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The microtubule (MT) system is important for many aspects of neuronal function, including 
motility, differentiation, and organelle trafficking.  The dysregulation of this system can 
therefore have a significant impact on neuronal function and survival.  Parkinson’s disease (PD) 
is associated with alterations in integrity of the axon/dendrites as well as axonal transport, which 
is suggestive of altered MT function.  In fact, recent studies using genetic and toxin models are 
beginning to implicate MT dysfunction as a key mechanism underlying neuronal degeneration in 
PD.  To further study the role of MT dysfunction in PD neurodegeneration, the effects of 
oxidative stress, which plays a key role in PD pathogenesis, on MT function were examined 
using the commonly utilized PD toxin, 6-hydroxydopamine (6OHDA).  In response to 6OHDA-
induced oxidative stress in neuronal cells, significant alterations in MT function were observed 
with reductions in MT growth rate, increase in frequency of MT pauses/retractions, impaired end 
binding protein 1 (EB1) levels, and increase in levels of tubulin acetylation.  Impaired function 
of tubulin deacetylases, specifically sirtuin 2 (SIRT2), was observed in oxidatively-stressed cells.  
Restoration of tubulin deacetylase function rescued MT function and the neuritic degeneration 
phenotype observed in response to 6OHDA, suggesting that oxidative stress impairs MT 
function by altering tubulin acetylation.  In addition to its impact on the integrity of the neurite, 
oxidative disruption of MT function also affected MT-dependent nuclear transport, which could 
contribute to the selective declines in transcriptional responses of diseased dopaminergic 
neurons.  In all, this study provides support for the role of MT dysfunction in the degenerative 
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processes seen in PD.  Elucidating how oxidative stress-induced changes in MT function can 
lead to neuronal degeneration will provide key insight into the development of novel therapeutic 
strategies. 
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1.0  INTRODUCTION 
Neurodegenerative diseases, such as Parkinson’s disease (PD), are associated with alterations in 
the integrity of the axon/dendrites, axonal transport of organelles, and gene expression in 
affected neurons [1-4].  Defining the mechanisms that underlie such alterations is crucial to 
elucidating the pathogenesis of PD and to the development of novel therapeutic strategies.  In the 
introduction that follows, I will lay the foundation for the studies that were carried out for this 
thesis with the goal of helping to advance our understanding of PD pathogenesis. 
1.1 PARKINSON’S DISEASE 
PD is the second most common neurodegenerative disease in the U.S. and the most common 
neurodegenerative movement disorder [5].  Its incidence increases with age, which is the primary 
risk factor, and affects more than 1 million Americans [5].  It is clinically characterized by 
resting tremor, bradykinesia (slowed movement), rigidity, and postural instability [6].  
Pathologically, it is characterized by a predominant loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNpc), which project to the striatum where they release 
dopamine and regulate key circuits involved in movement control [4].  The presence of 
eosinophilic cytoplasmic inclusions, called Lewy bodies, is also a hallmark pathologic feature of 
the remaining dopaminergic neurons [4].  Although impaired nigro-striatal dopaminergic 
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projection accounts for the cardinal motor symptoms of the disease, it does not explain the many 
non-motor symptoms that are also found in patients with PD, such as cognitive impairment, 
autonomic dysfunction, sensory alterations, and psychiatric issues [6].  Lewy bodies have also 
been found in the peripheral nervous system of PD patients [7].  The presence of these symptoms 
and pathologic features suggests that neurons in other regions of the brain as well as outside the 
brain are also affected  – making the proper treatment of this disease more difficult [4]. 
1.1.1 Role of Oxidative Stress in PD Pathogenesis 
In addition to the study of human post-mortem PD brains, studies utilizing genetic and toxin 
models of PD have provided valuable insight into the pathogenesis of the disease, including the 
importance of oxidative stress in the development and/or progression of the disease.  In the 
oxidative stress hypothesis, it is thought that an imbalance in cellular levels of reactive oxygen 
species (ROS) causes damage that ultimately leads to cell death.  There is a fair amount of 
support for the oxidative stress hypothesis, including evidence from post-mortem brains as well 
as animal and cell culture models.   
The high level of aerobic respiration (~20% of the resting total body oxygen) combined 
with lower levels and/or activities of antioxidants, such as glutathione, superoxide dismutase 
(SOD), catalase, and vitamin E, in the brain make it prone to oxidative damage [8,9].  
Furthermore, given its unique biology, the nigral dopaminergic neurons are even more 
susceptible to degeneration.  Dopamine is chemically unstable and can undergo autoxidation to 
form ROS and quinones/semiquinones, which themselves can also act as oxidants – all of which 
can support ROS formation [8,10].  Monoamine oxidase-medicated catabolism of dopamine can 
also generate ROS [11,12].  In addition, elevated levels of iron in regions such as the substantia 
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nigra can contribute to hydroxyl radical (OH∙) production via Fenton chemistry [8,13].  The 
antioxidant glutathione (GSH) is found in both mitochondrial and cytosolic compartments and 
plays a key role in scavenging ROS and reactive nitrogen species (RNS) as well as helping to 
recycle other antioxidants [14].  GSH levels in the substantia nigra are lower than other brain 
regions like the cortex, cerebellum, and hippocampus and these levels also decline (~30%) in an 
age-dependent manner [14].  In fact, a further depletion of total glutathione (reduced and 
oxidized forms) in the substantia nigra is an early biochemical hallmark of PD [15,16].  
Although other antioxidants, such as catalase, are also reduced in PD, the degree of GSH 
depletion parallels the severity of the disease [14,17].  Additionally, mitochondria play a major 
role in producing cellular ROS and hence impairment in mitochondrial respiratory chain, such as 
decreased complex I activity as observed in substantia nigra of PD brains, can further increase 
ROS production [18,19].   
Increases in cellular ROS can cause significant damage to macromolecules and, in fact, 
there is a significant amount of evidence of oxidative damage in PD brains.  There are increases 
in markers of lipid oxidation, such as malondialdehyde and 4-hydroxy-2-nonenal, compared to 
age-matched controls [20,21].  Interestingly, 4-hydroxy-2-nonenal can cause irreversible changes 
to α-synuclein, a protein that is implicated in the pathogenesis of PD, such that it may be prone 
to adopt more of a pathological (protofibril) confirmation that can cause neurotoxicity [22].  In 
addition, there is an increase in oxidative damage of proteins, such as carbonyl modifications as 
well as cross-linking and fragmentation [23,24].  Oxidative stress has been shown to cause many 
different types of DNA lesions as well – a very common and extensively studied lesion is 
formation of 8-oxodeoxyguanine (8-oxodG) [25,26].  Oxidative damage to DNA is observed in 
the substantia nigra from PD brains as evidenced by an increase in 8-oxodG levels in nuclear and 
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mitochondrial DNA compared to age-matched controls [27-29].  The cell has a few mechanisms 
to remove these DNA lesions and the primary enzyme responsible for this is 8-oxoguanine 
glycosylase (OGG1).  Recent studies have shown that there is an up-regulation of a 
mitochondrial OGG1 in the substantia nigra of PD brains, likely as a compensatory response to 
oxidative damage [30].  Such alterations in the integrity of DNA can have significant impact on 
mitochondrial function and on gene transcription.     
Genetic and toxin models of PD provide further support for the oxidative stress 
hypothesis in PD pathogenesis [31-35].  Mutations or deficiency of the proteins associated with 
familial PD, e.g. α-synuclein, Parkin, PINK1 (PTEN-induced kinase 1), DJ-1, and LRRK2 
(leucine-rich repeat kinase 2), increase susceptibility of cells to oxidative stress-mediated cell 
death [32,36,37].  Parkinsonian mimetics such as, 6-hydroxydopamine (6OHDA), 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, and paraquat, are well-utilized toxin 
models of PD that generate ROS and can lead to neuronal death [31,34,38].  Hence, studies in 
various models of PD suggest that oxidative stress has an important role in the development 
and/or progression of the disease.   
1.1.2 6-hydroxydopamine – Model of PD-Relevant Oxidative Injury 
6OHDA has been widely used, in vivo and in vitro, to study neuronal injury responses in PD 
[12,39].  Isolated in 1959, it is a hydroxylated analog of catecholamine neurotransmitters that is 
taken up into cells by dopamine and norepinephrine reuptake transporters [12,39].  Early studies 
with systemic administration of the toxin showed depletion of noradrenaline in the nerves to the 
heart as well as damage to nerve endings of sympathetic neurons [40-45].  However, with a 
systemic application of the toxin, no CNS lesion is observed since 6OHDA cannot cross the 
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blood-brain barrier.  In order to achieve pathology similar to what is seen in PD patients, 
6OHDA is administered intracerebrally, typically in the striatum, substantia nigra, or the 
ascending medial forebrain bundle that contains the nigrostriatal tract [12].  With such 6OHDA 
applications, striatal dopamine is depleted and nigral dopaminergic neurons are damaged.  The 
time course of injury does vary depending on where 6OHDA was injected, with a substantia 
nigra or medial forebrain bundle injection showing evidence of degeneration sooner than 
injection into the striatum [46-49].  Behaviorally, many tests to model PD clinical features, e.g. 
postural and gait abnormalities, dyskinesias, rigidity, resting tremors, and responsiveness to L-
DOPA, have been developed and validated with the 6OHDA injury model [39,50].         
 The primary mode of 6OHDA-induced neurodegeneration is through the generation of 
ROS and quinones [12,51].  Quinones could contribute to toxicity via a ROS-independent 
mechanism (e.g. reacting with various amino acid residues).  However, ROS are thought to be 
the primary toxic mediators as recycling of the quinones by ascorbic acid into 6OHDA with a net 
formation of hydrogen peroxide (H2O2) enhances neurotoxicity [38].  The formation of ROS by 
6OHDA is likely to occur via multiple mechanisms, such as auto-oxidation, catalysis by 
monoamine oxidase, and its effects on mitochondrial function.  Molecular oxygen and a redox-
capable transitional metal are necessary for the chemical reaction to convert 6OHDA into 
quinones plus H2O2 [38].  Figure 1 shows the overall reaction for 6OHDA oxidation; however 
this reaction is more complicated as it proceeds through various intermediate steps involving 
formation of semiquinones and superoxide [38,52].   
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OHHO
HO NH2
+   O2
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+   H2O2
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Figure 1:  6OHDA Oxidation 
In the presence of molecular oxygen and transitional metals, such as iron or copper, 6OHDA is oxidized into a para-
quinone and H2O2 through a series of intermediate steps.  Adapted from [38]. 
 
Iron, which is elevated in the substantia nigra of PD brains, can react with H2O2 via 
Fenton chemistry to produce the very reactive hydroxyl radical [8,13].  Therefore, iron chelating 
agents have been shown to be protective against 6OHDA toxicity [53,54].  Furthermore, as is 
seen with dopamine, monoamine oxidase can catalyze 6OHDA to produce H2O2 as one of the 
side products [55,56].  The formation of ROS, e.g. H2O2, superoxide, and hydroxyl radical, has 
been shown to occur in vivo as well as in vitro and antioxidants, e.g. catalase, glutathione 
peroxidase, manganese superoxide, and metalloporphyrins, have been shown to protect against 
6OHDA – all of which strongly support a ROS-mediated 6OHDA toxicity mechanism [57-72].    
 The oxidative imbalance that is created in cells exposed to 6OHDA impacts many aspects 
of cellular function.  A key effect is on mitochondria as their dysfunction is thought to be an 
important factor in neuronal degeneration seen in PD [71,73,74].  6OHDA has been shown to 
inhibit complexes I and IV of isolated mitochondria, uncouple oxidative phosphorylation, and 
collapse the mitochondrial membrane potential [63,73,75].  Mitochondrial dysfunction can 
increase the production of ROS [18,19].  Interestingly, in addition to the early autoxidation phase 
of ROS production, there is evidence of a delayed phase of mitochondrial ROS production in 
6OHDA-treated cells [71].  Hence, mitochondrial dysfunction represents yet another way in 
which 6OHDA increases cellular ROS levels.   
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Although used as an exogenous neurotoxin, several studies have provided evidence that 
6OHDA could also be a physiological endogenous neurotoxin [12].  6OHDA has been observed 
in the brains of humans and rats and has also been detected in urine of patients treated with L-
DOPA [12,76,77].  Furthermore, dopamine reactions with free iron and its oxidization in the 
presence of various agents, such as nitrite ions or manganese, can generate 6OHDA [78-82].     
Given the possibility of endogenous production of 6OHDA and its ability to create 
pathological lesions, molecular alterations, and behavioral symptoms similar to those seen in PD, 
6OHDA continues to be a very meaningful model for studying neuronal degeneration seen in PD 
and in testing new neuroprotective strategies. 
1.2 THE MICROTUBULE SYSTEM 
Microtubules (MTs) are one of the principle components of the cellular cytoskeleton and play an 
important role in many cellular processes, such as cell division, organelle trafficking, cell 
motility, and neuronal differentiation.  MTs are hollow fibers with a diameter of approximately 
25nm that are assembled from heterodimers of α-tubulin and β-tubulin [83].  These heterodimers 
polymerize from head-to-tail to form protofilaments and 13 of these protofilaments arrange in 
parallel to form a cylindrical microtubule lattice [83].  The arrangement of the tubulin dimers 
creates a polarity with a minus-end and a plus-end.  The minus-end is anchored by the 
centrosome, which is the major microtubule-organizing center in animal cells [83].  Hence, MT 
assembly initiates at the centrosome (which is typically near the nucleus) and MTs elongate from 
their plus-ends (growing away from the nucleus and towards the periphery).  γ-tubulin ring 
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complexes are the key components in the centrosome that are responsible for the nucleation of 
MTs [83].               
1.2.1 Dynamic Instability  
Microtubules switch between phases of growth (polymerization) and shrinkage 
(depolymerization) – a property known as dynamic instability [83,84].  The shift from growth to 
shrinkage is termed “catastrophe” and the shift from shrinkage to growth is termed “rescue”.  
This process is driven by the hydrolysis of GTP (guanosine triphosphate) on β-tubulin.  Although 
GTP also binds to α-tubulin, this pool of GTP is never hydrolyzed [83].  Soon after incorporation 
into the growing MT, GTP bound to β-tubulin is hydrolyzed.  Hence, along the length of the MT, 
β-tubulin is bound to GDP (guanosine diphosphate).  The conformation of the tubulin dimer 
depends on whether β-tubulin is bound to GTP or GDP.  GTP-bound tubulin dimer has a 
relatively straight conformation while GDP-bound tubulin dimer has a more curved 
conformation [84].  While part of the MT wall, GDP-bound tubulin dimer is prevented from 
adopting the curved conformation by bonds (lateral and longitudinal) with adjacent tubulin 
dimers [84].  At the plus-end of the MT, a ‘cap’ of GTP-bound β-tubulin is found and serves to 
stabilize, by lateral bonds, the final layer of GDP-bound β-tubulin [84].  If the GDP-bound 
tubulin dimer is allowed to take its curved conformation, as is the case when the ‘cap’ is 
removed, MT depolymerization occurs.  Depolymerized tubulin exchanges GDP for GTP and the 
cycle begins once again.  The rate of tubulin addition compared to rate of GTP hydrolysis plays 
an important role in determining whether a MT grows or shrinks: growth if the rate of tubulin 
incorporation is greater than hydrolysis of GTP and shrinkage if rate of GTP hydrolysis is greater 
than the rate of tubulin incorporation [83]. 
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1.2.2 Regulation of MT Dynamics 
MT dynamics is regulated by a large network of proteins that interact with one another in a 
complex manner [83-86].  These proteins, referred to as MT-associated proteins (MAPs), serve 
to stabilize or destabilize the MT structure spatially and temporally [86].  There are many 
categories, with some overlap, of MAPs in eukaryotes, such as structural MAPs, MAPs with 
enzymatic activity, motor proteins, centrosome-associated proteins, and MT plus-end tracking 
proteins [84,86-89].  Two of the most studied MAPs, particularly with regards to neurons, are tau 
and MAP2.  They have been traditionally used to highlight different regions of a neuron, 
specifically in identifying axons (tau) versus dendrites (MAP2) [87].  These MAPs stabilize the 
MT lattice and regulate many aspects of neuronal function, such as neurite initiation, signal 
transduction, MT spatial organization, and MT-dependent transport [87].   
 A major group of MAPs are the plus-end tracking proteins (+TIPs), which are conserved 
in all eukaryotes [84,85].  +TIPs, of which more than 20 have been described thus far, share the 
ability to bind to the plus-ends (growing ends) of MTs, where they play a significant role in 
regulating MT dynamics [84-86].  Although they belong to many structurally unrelated families, 
+TIPs share some evolutionarily conserved repeat sequences, domains, and motifs [85].  In 
addition to regulating MT dynamics, +TIPs also play an important role in MT nucleation and 
linking MTs to vesicles and macromolecules, cell membrane, actin cytoskeleton, kinetochores, 
and focal adhesions [84,85].  The end binding (EB) protein family of +TIPs are a particularly 
important group of proteins in the regulation of MT dynamics.  There are three EBs in mammals, 
EB1-3, and they can track MT plus-ends autonomously, which is in contrast to most other +TIPs 
that require other factors for their MT binding [90,91].  EBs possess an EB homology domain 
that facilitates interactions with other +TIPs, which serves as one of the main mechanisms by 
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which other +TIPs interact with MT plus-ends [84].  EBs also contain domains for interactions 
with MTs at their plus-ends (calponin homology domain) and for homo- and heterodimerization 
(coiled-coil domain) [84,85].  In terms of MT dynamics, EBs promote MT growth by 
mechanisms such as increasing the frequency of MT rescue and reducing catastrophes and time 
spend pausing [91-94].  In neurons, EBs have also been shown to be important for axonal 
transport and establishing neuronal polarity [95,96].  Importantly, EBs are central players in 
regulating MT function since most +TIPs have been shown to interact with and be regulated by 
EBs [85,89].   
1.2.3 Regulation of MT Function by Post-Translational Modifications 
MT function is also regulated by post-translational modifications (PTMs) of the tubulin subunit, 
such as acetylation, tyrosination and detyrosination, polyglutamylation, palmitoylation, 
polyglycylation, and phosphorylation [97,98].  Different regions of a neuron show different 
patterns of tubulin PTMs – e.g. tyrosination is mostly seen in the growth cone and dendrites 
(more dynamic MTs), detyrosination and acetylation is mostly seen along the axon (more stable 
MTs), and polyglutamylation is seen throughout the neuron [97,98].  It is thought that MTs with 
a greater half-life accumulate specific modifications, such as acetylation and detyrosination.  
Hence, different tubulin PTMs help identify different pools of MTs – long-lived (stable) MTs are 
enriched in detyrosinated and acetylated tubulin whereas more dynamic MTs are enriched in 
tyrosinated tubulin [97,98].  Table 1 summarizes the subcellular distribution of the four major 
tubulin PTMs in neurons.  
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Table 1:  Tubulin PTMs in Neurons 
Modification: Marker: Neuronal Distribution 
(Predominant): 
 
Tyrosination 
 
 
Dynamic MTs 
 
Distal axon and growth cone 
 
Detyrosination 
 
 
Stable MTs 
 
Proximal axon 
 
Acetylation 
 
 
Stable MTs 
 
Proximal axon 
 
Polyglutamylation 
 
Not a MT marker 
 
Found on all MTs but precise 
localization of subtypes is unclear 
 
 
Furthermore, in addition to serving as markers, tubulin PTMs have important functions in 
regulating MT-dependent processes.  Several studies have recently shown that tubulin PTMs can 
regulate the binding of MAPs to MTs.  For example, binding of kinesin and various +TIPs is 
regulated by the tyrosination status of tubulin, kinesin-1 and dynein are recruited by acetylated 
MTs, and polyglutamylation of tubulin regulates binding of kinesin and dynein motors along 
with numerous +TIPs [97-100].  Furthermore, given that different PTMs can coexist on the same 
tubulin molecule, the regulation of MAPs could be mediated by a combination of such PTMs in 
neurons [101-103].  In short, post-translational modification of MTs likely plays an important 
role in many aspects of neuronal function, such as differentiation, transport of cargo, axon 
guidance, and synapse formation. 
Acetylation of tubulin occurs on the Lysine-40 residue of α-tubulin, which is predicted to 
face the MT lumen [97,104,105].  Recently, a novel acetylation site on β-tubulin (Lys-252) has 
been identified along with proteomic identification of numerous possible acetylation sites on α-
tubulin and β-tubulin [106,107].  Many of these sites are predicted to be on the outside surface of 
the MT lattice – allowing for more straightforward mechanisms to regulate binding of MAPs.  
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Acetylation is a marker of stable MTs but whether it causes MTs to become stable and affects its 
dynamics is not certain as there are conflicting reports.  These studies have approached this 
question primarily by regulating the function of one of the two known tubulin deacetylases, 
HDAC6 (histone deacetylase 6; discussed in detail later).   
Matsuyama et al., utilizing NIH 3T3 cells, showed that using trichostatin A (TSA), which 
inhibits class I and II histone deacetylases (HDACs) including HDAC6, increased tubulin 
acetylation levels, increased MT polymer content, and made the MTs more resistant to early 
depolymerization by the MT-depolymerizing agent demecolcine (colcemid; 1μM; up to 30min; 
no protection by 1hr) [108].  Treatment with trapoxin (TPX), which inhibits class I and II 
HDACs but not HDAC6, did not reproduce the results seen with TSA.  Overexpression of 
HDAC6 was shown to accelerate demecolcine-induced MT depolymerization [108].  These 
results suggested that inhibition of HDAC6 and subsequent increase in tubulin acetylation could 
lead to MT stability.  However, a couple of studies that were published in 2003 contradicted the 
conclusion that increased acetylation affects MT stability [109,110].  The study by Haggarty et 
al. utilizing A549 lung carcinoma cells showed that treatment with tubacin, a HDAC6-specific 
inhibitor, did not change the sensitivity to cold depolymerization or to nocodazole (332nM; 
2hrs), a depolymerizing agent [110].  Palazzo et al. showed that NIH 3T3 cells treated with TSA 
have increased tubulin acetylation levels but do not show any changes to nocodazole-induced 
depolymerization (10μM; 30min) or changes in the amount of detyrosinated tubulin, a marker of 
stable MTs [109].  These studies suggest that an increase in MT acetylation by HDAC6 
inhibition does not affect MT stability.  A study by Dong-Anh Tran et al. in 2007 utilizing 
various cell types supported and expanded on the initial study by Matsuyama and coworkers, 
emphasizing the importance of tubulin acetylation in regulating the dynamic properties of MTs 
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[111].  These authors showed that treatment with TSA reduced rates and percentage of time 
spent depolymerizing / polymerizing.  Reduction in dynamicity (measured as total distance of 
polymerized and depolymerized MTs divided by total elapsed time) was also observed.  
However, frequency of rescue and catastrophe was not affected.  HDAC6 KO mouse embryonic 
fibroblast (MEF) cells showed an increase in the time spent pausing and this effect was rescued 
by overexpression of HDAC6.  HDAC6 KO MEFs did not show any changes in the rate of 
depolymerization / polymerization or in the frequency of rescue and catastrophe.  However, 
resistance to nocodazole treatment (10μM; protection up to 30min-1hr) was observed in TSA-
treated NIH-3T3 cells, HDAC6 KO MEFs, and HDAC6 knock-down A549 cells.  Finally, TSA 
treatment also protected against end-mediated depolymerization induced by ATP [111].  Hence, 
as can be noted from the above studies, there is some disagreement when it comes to the question 
of whether increased acetylation affects MT function.  However, it is likely that differences in 
sensitivity of the assays, method used to increase acetylation levels, variable drug concentrations, 
and variable treatment times combine to explain why the results are contradictory.  Supporting 
this is the study by Dong-Anh Tran et al., which showed differences in MT dynamics with 
tubulin acetylation.  When the authors used less sensitive assays, such as the ones used by the 
groups that showed no differences, they also did not observe any differences in cells with 
hyperacetylated MTs [111].  Hence, the assays used to study MT dynamics are an important 
consideration for these studies.  In addition, through manipulation of tubulin acetylation via taxol 
and HDAC6 in fibroblast and neurons, Sudo et al. found that acetylation of tubulin leads to 
severing of MTs by katanin, which could be a way to destabilize acetylated MTs [112].  In 
conclusion, more studies using assays with greater sensitivities and examining more direct 
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effects of tubulin acetylation are required to fully elucidate the impact of acetylation on MT 
dynamics.        
1.2.4 Tubulin Acetylases 
Tubulin acetylases have only been recently identified but have provided insight into the role of 
tubulin acetylation for neuronal function.  Ohkawa et al. showed that ARD1 (ADP-ribosylation 
factor domain protein 1) in complex with NAT1 (N-terminal acetyltransferase) can acetylate α-
tubulin [113].  Mutant ARD1 with reduced acetyltransferase activity or knock-down of ARD1 
reduced dendritic extensions in cultured Purkinje cells.  Interestingly, the overexpression of 
ARD1 was able to rescue HDAC6-mediated reduction in dendritic arborization, suggesting a 
common substrate (e.g. α-tubulin) may be involved [113].   
 Another tubulin acetylase was also recently identified – the Elongator complex [114].  
The authors showed that key subunits, Elp1 and Elp3, of the complex interact with MTs and 
regulate the acetylation of α-tubulin in various cell types, including cortical projection neurons.  
Overexpression of a dominant-negative α-tubulin that cannot be acetylated on Lys-40 (K40A) 
impaired neuronal migration and branching, a phenotype that was also seen after Elp1/Elp3 
knock-down.  Inhibition of HDAC6 by the specific inhibitor tubacin restored tubulin acetylation 
levels in the Elp1/Elp3 knock-down cells and also rescued the branching defects in Elp3-
depleted cortical neurons.  These data suggest that tubulin acetylation is directly involved in 
regulating neuronal differentiation.     
MEC-17 and its homolog αTAT1 have also been recently identified as an α-tubulin 
acetylase at Lys-40 in Tetrahymena thermophila, C. elegans, and in zebrafish, where they may 
play an important role in nervous system development and touch sensation [115,116].  The 
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acetylation of other substrates in regulating these processes is yet to be determined.  San, an 
acetyltransferase, has also been recently identified to acetylate a site in β-tubulin, Lysine-252, 
which affects its incorporation into growing MTs [106].  In addition, general control of amino 
acid synthesis 5 (GCN5) has been shown to be recruited to MTs during muscle cell 
differentiation via a cytoplasmic cleavage produce of the Myc transcription factor and leads to 
Lys-40 acetylation of α-tubulin [117].  Hence, there are many tubulin acetylases, depending on 
the tissue and organism examined, and it is likely that others are yet to be identified. 
1.2.5 Tubulin Deacetylases 
Most studies examining the effects of tubulin acetylation on MT function have focused on 
manipulating acetylation levels via regulation of the two tubulin deacetylases – HDAC6 (histone 
deacetylase 6) and SIRT2 (sirtuin 2).  There are four categories of HDACs based on their protein 
sequence and structure: (1) class I includes HDAC1, HDAC2, HDAC3, and HDAC8, (2) class II 
includes HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10, (3) class III includes the 
silent information regulators (sirtuins or SIRTs) from 1 to 7, and (4) class IV consists of 
HDAC11 [118,119].  The subcellular localization of these proteins varies depending on the 
specific deacetylase; however, in general, class I members are mostly in the nucleus, class II and 
IV members are found both in the nucleus as well as the cytoplasm and can undergo 
nucleocytoplasmic trafficking, and class III members can be found in the nucleus, cytoplasm, or 
mitochondria [119,120].  Hence, despite possessing the name “histone deacetylase”, many of the 
HDACs also deacetylate substrates other than histones [119,120].     
HDAC6 is a class II HDAC that is unique amongst other HDACs in that it possesses two 
catalytic domains [121].  The deacetylase domain is conserved among the other class I and II 
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HDACs and is formed by a stretch of approximately 390 amino acids [119].  Key histidine, 
aspartic, and tyrosine residues along with a Zn2+ ion are involved in a charge-relay system to 
remove the acetyl group [122,123].  Whether both catalytic domains are important for the full 
deacetylase activity of HDAC6 is uncertain as there are conflicting reports [118].  HDAC6 also 
contains a Ser-Glu-containing tetradecapeptide (SE14) repeat domain that is important for 
cytoplasmic anchoring, a nuclear export signal (NES) that is important for its export to the 
cytoplasm, and a zinc finger domain that is important for binding to ubiquitin [121,124,125].   
HDAC6 has numerous substrates, including α-tubulin, cortactin, and heat shock protein 
90 (Hsp90) in vivo and histones in vitro [118,126].  Given the various substrates and other 
interacting proteins, HDAC6 regulates many cellular systems, such as the MT and actin 
cytoskeletons and the protein chaperone system [118,126].  Some MT-dependent functions of 
HDAC6 have been discussed in previous sections, but a key function is in the recruitment of 
motor proteins, such as dynein and kinesin-1, to MTs to regulate processes such as cargo 
trafficking, e.g. mitochondria, brain-derived neurotrophic factor (BDNF), and polyubiquitinated 
protein aggregates for autophagic clearance [127-130].  In neurons, the polyubiquitination 
function of HDAC6 plays an important role in dendritic differentiation by regulating the Cdc20-
anaphase-promoting complex (APC) ubiquitin signaling pathway [131].  Furthermore, HDAC6 
has been shown to be important for the formation of the axon initial segment and for axonal 
growth likely by regulating tubulin acetylation [132]. 
 It is not certain if several of the MT-dependent processes regulated by HDAC6 are only 
due to its effect on tubulin acetylation.  Interestingly, HDAC6 has been shown to interact with 
and regulate MAPs, such as tau and EB1 [133-136].  Tau is an important MT stabilizing MAP 
and EB1 is a key regulator of the dynamic properties of MTs [87,89].  Work by Zilberman et al. 
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in non-neuronal cells showed that inhibition of HDAC6 activity, either via the specific inhibitor 
tubacin or mutation of one the deacetylase domains but not both domains, reduced MT growth 
velocities [136].  However, knock-down of HDAC6 did not show such results, leading the 
authors to conclude that an inhibited HDAC6 is needed to negatively affect MT dynamics.  They 
further propose a model where binding of EB1 to MT plus-ends is altered by a defective 
HDAC6, however further studies are required to support this hypothesis.  Nonetheless, HDAC6-
mediated effects on MAPs along with its effects on MT acetylation likely combine to regulate 
MT-dependent processes in neurons.    
 SIRT2 is a class III HDAC and needs nicotinamide adenine dinucleotide (NAD+) as a 
cofactor for its deacetylase activity [120].  The catalytic domain is conserved in all SIRTs and is 
a stretch of 275 amino acids [120].  Key histidine, glutamine, asparagine, and aspartic residues 
have been shown to be important for its enzymatic activity [137].  SIRT2 also contains a 
canonical NES to export it out of the nucleus [138].  The detailed chemical mechanism of the 
SIRT2 deacetylase reaction needs to be clarified, however it is known that the reaction produces 
nicotinamide, an endogenous SIRT inhibitor, and O-acetyl-ADP-ribose (OAADPr) as side 
products [139,140].  SIRT2 has numerous known substrates, including α-tubulin, p53, FOXOs, 
and histones [141,142].  SIRT2 has been shown to co-localize and co-immunoprecipitate with 
HDAC6 and in vivo both proteins may be present in a complex that regulates MT deacetylation 
[143].  There are very few studies examining the role of SIRT2 in neurons but it has been shown 
to negatively regulate, in a deacetylase-dependent manner, neurite outgrowth and growth cone 
dynamics in hippocampal neurons [141,144].  SIRT2 has also been shown to promote axonal 
degeneration in a Wallerian degeneration model [145].  Given the importance of MTs in these 
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processes, these effects of SIRT2 may result from MT alterations; however, this has not been 
established and further studies are required to determine the specific substrates involved.  
1.2.6 MT Dysfunction in PD 
Axonal degeneration is one of the earliest features of neurodegenerative diseases, such as PD 
[4,146].  The MT system is crucial to the proper development and maintenance of axons, and 
hence axonal retraction is indicative of MT dysfunction [147].  Furthermore, axonal transport of 
cargo, such as organelle and protein complexes, is essential for proper neuronal biology [3,148].  
MTs, which are nearly uniform in polarity as the plus-ends face the synapse and the minus-ends 
face the cell body, along with motor proteins, which show preferences for plus- and minus-ends, 
are the key elements of axonal transport [2].  Interestingly, there is an extensive amount of 
evidence of altered axonal transport of cargo in neurodegenerative diseases [2,148].  In PD, 
evidence of altered axonal transport comes from both genetic and toxin models.  Mutations in α-
synuclein, which is associated with familial PD, show reduced transport along axons and 
abnormal protein accumulation compared to the wild-type protein [149].  Aggregation of α-
synuclein can impair MT-dependent transport while not affecting MT-independent trafficking 
[150].  In an α-synucleinopathy rat model, reductions in various anterograde motor proteins and 
an increase in retrograde motor proteins were found in the striatum [151].  In Drosophila larval 
motor neurons, PINK1 overexpression reduced mitochondrial transport (anterograde and 
retrograde) and knock-down of PINK1 increased anterograde transport [152].  MPP+ has been 
shown to impair movement of membrane-bound organelles, such as mitochondria, along axons / 
neurites [153-155].  In fibroblasts and SH-SY5Y neuroblastoma cells, rotenone treatment was 
shown to reduce mitochondrial motility [156,157].  However, chronic rotenone exposure in 
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neurons has been shown to increase mitochondrial retrograde transport [158].  Dopamine 
neurons with deficient respiratory chain function (MitoPark mouse), which is a key hallmark of 
PD, have reduced anterograde axonal transport of mitochondria [159].   
 The alterations in axonal integrity and transport are highly suggestive of MT dysfunction.  
In fact, in various models of PD, MT alterations are beginning to be identified.  Parkin, 
mutations in which are associated with familial PD, has been shown to interact with tubulin 
heterodimers and MTs and reduces colchicine-induced depolymerization of MTs [160].  α-
synuclein co-localizes with tubulin in Lewy bodies as well as other α-synuclein-positive lesions 
[161].  Tubulin can also promote α-synuclein fibril formation in vitro [161].  α-synuclein binds 
tubulin and the wild-type (WT) protein, but not mutants, can promote its polymerization into 
MTs [162].  Overexpression of α-synuclein and subsequent aggregation led to the 
disorganization of the MT network in cells and also causes co-aggregation of tubulin but not β-
actin [150].  In the striatum of an α-synucleinopathy rat model, reduction in α- and γ-tubulin 
levels is observed [151].  Hence, α-synuclein and tubulin biology may be closely linked.  
LRRK2, mutations in which are also associated with familial PD, has been strongly linked to 
MTs as well [163].  LRRK2 binds tubulin and regulates phosphorylation of β-tubulin that is 
enhanced by the PD mutant G2019S, causing stability of MTs in the presence of MAPs 
[164,165].  LRRK2 was shown to increase tubulin polymerization and this has been linked to 
aggregation of α-synuclein and subsequent neuropathology in A53T α-synuclein mice [166].  
Furthermore, WT and mutant LRRK2 proteins also play an important role in regulating 
interaction of tau with MTs as well as tau phosphorylation levels [167-169].  These data suggest 
that LRRK2 plays an important role in regulating MT function.  Toxin models of PD, such as 
rotenone and MPP+, also provide further support of MT dysfunction.  Rotenone causes 
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depolymerization of MTs in TH (tyrosine hydroxylase)-positive neurons, which was blocked by 
taxol treatment [170].  In addition, rotenone can bind tubulin and inhibit its polymerization in 
vitro [170].  MPP+ reduces tubulin polymerization in vitro and in vivo [171,172].  MPP+ has 
also recently been shown to reduce MT growth rates in differentiated PC12 cells along with 
causing alterations in tubulin PTMs, such as reducing tyrosinated tubulin and increasing 
acetylated tubulin [154].  As can be noted from these studies, there is growing evidence from 
various models that MT dysfunction may play an important role in the neuronal degeneration 
that is seen in PD.            
1.2.7 Oxidative Stress & MT Dysfunction 
A few studies have provided evidence of MT dysfunction in models of oxidative stress.  In 
human osteosarcoma 143B cells, H2O2 treatment (200 – 400μM; 48hrs) resulted in increased 
levels of monomeric tubulin and decreased levels of polymerized tubulin, suggesting increased 
depolymerization and/or reduced polymerization [173].  In HeLa cells, H2O2 treatment (200μM; 
4hrs) causes reduction in EB1 levels as well as EB1 “comet” length, which is correlated with 
decreased MT growth velocities [174-177].  Treatment for 45min with 200uM H2O2 caused 
alterations in MT dynamics, such as reduced growth rate, increased shortening rate, and 
increased time spent pausing [174].  Cysteine oxidation has been shown to reduce 
polymerization of tubulin into MTs [178-183].  Quinones (e.g. benzoquinone), which are linked 
to oxidative stress, can disrupt cellular MT organization in NIH 3T3 cells and reduce 
polymerization of tubulin in vitro [184].  Hence, the MT system is thought to be sensitive to 
oxidative stress.  However, these studies have been done in non-neuronal cells and hence not 
much is known with regards to the effects of oxidative stress on MT function in neuronal cells. 
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2.0  RATIONALE AND HYPOTHESIS 
The MT system is important for many aspects of neuronal function and the dysregulation of this 
system may play a key role in neuronal degeneration.  Oxidative stress, which is implicated in 
the pathogenesis of many neurodegenerative diseases such as PD, has been linked to MT 
dysfunction; however these studies utilize high doses of oxidative stressors and have been 
carried out in non-neuronal cells.  Therefore, utilization of a PD-relevant sub-lethal oxidative 
injury model can provide valuable insight into the neuronal degeneration observed in this 
disease.  The overall goal of this study was to examine the effects of oxidative stress, as induced 
by the commonly utilized PD toxin 6OHDA, on MT function in neuronal cells.  It is 
hypothesized that 6OHDA-induced oxidative stress alters MT dynamics and results in 
impairment in MT-dependent processes, such as neuritic growth / maintenance.  The restoration 
of the dynamic properties of MTs is further hypothesized to reverse the effects on neuritic 
integrity and provide key insight into the mechanisms involved in the degeneration of neurons in 
PD as well as into potential therapeutic strategies.    
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3.0  MATERIALS AND METHODS 
3.1 TISSUE CULTURE 
Human SH-SY5Y neuroblastoma cells (ATCC, Manassas, VA) were grown on 10cm cell culture 
dishes containing Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal calf serum 
(BioWhittaker, Walkersville, MD), 2mM L-glutamine (BioWhittaker, Walkersville, MD), and 
10mM HEPES (BioWhittaker, Walkersville, MD).   For retinoic acid (RA) differentiation 
(Sigma-Aldrich, St. Louis, MO), cells were plated in 10μM RA for 3 days prior to any 
experimental manipulations, such as transfections or drug treatments, and then maintained in 
RA-containing media for the duration of the experiment.  Cells were maintained at 37oC in a 
humidified 5% CO2 incubator.   
3.2 PLASMIDS & TRANSFECTIONS 
SH-SY5Y cells were transfected with LipofectamineTM 2000 reagent (Invitrogen, Carlsbad, CA) 
utilizing Opti-MEM® I reduced serum media (Invitrogen, Carlsbad, CA) according to the 
manufacture’s protocol at a final Lipofectamine concentration of 0.1%.  Undifferentiated SH-
SY5Y cells were grown for at least 2 days before transfection and then allowed to express the 
protein of interest for another 48hr before treatment.  Differentiated SH-SY5Y cells were grown 
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for 3 days before transfection and then allowed to express the protein of interest for another 24hr 
before start of treatment.  The media was refreshed the day after transfection.   
 All plasmids were prepared with QIAGEN Plasmid Maxi Kit (Valencia, CA) as per the 
manufacturer’s protocol and their sequences were confirmed (Sequencing Core Facility, 
Genomics and Proteomics Core Laboratories, University of Pittsburgh, Pittsburgh, PA).  eGFP-
C1 (green fluorescent protein) plasmid was purchased from Clontech (Mountain View, CA).  
pcDNA 3.1 was purchased from Invitrogen (Grand Island, NY).  EB3-GFP, HDAC6-GFP, and 
SIRT2-GFP expression plasmids were kindly provided by Dr. Niels Galjart (Erasmus University, 
Rotterdam, The Netherlands), Dr. Francisco Sanchez-Madrid (Hospital Universitario de la 
Princesa, Instituto de Investigaciόn Sanitaria Princesa, Madrid, Spain), and Dr. Eric Verdin 
(UCSF, San Francisco, CA), respectively.  HDAC6-FLAG and SIRT2-FLAG were purchased 
from Addgene (Cambridge, MA).  EB3-mCherry was produced via standard subcloning 
techniques.  Briefly, EB3-GFP and mCherry-N1 (Clontech, Mountain View, CA) were cleaved 
with EcoRI (New England BioLabs, Ipswich, MA) and BamHI (New England BioLabs, Ipswich, 
MA) for 1hr at 37oC and the cleaved products were separated on a 2.5% agarose (Invitrogen, 
Carlsbad, CA) gel.  The EB3-GFP fragment and cleaved mCherry-N1 were cut from the gel and 
extracted with QIAquick Gel Extraction Kit (QIAGEN, Valencia, CA) as per the manufacturer’s 
protocol.  Extracted DNAs were then ligated overnight with the Fast-LinkTM DNA Ligation Kit 
(Epicentre Biotechnologies, Madison, WI) as per the manufacturer’s protocol.  The sequence of 
the ligated product, EB3-mCherry, was then confirmed (Sequencing Core Facility, Genomics 
and Proteomics Core Laboratories, University of Pittsburgh, Pittsburgh, PA).         
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3.3 PHARMACOLOGICAL TREATMENTS 
Retinoic acid was prepared in dimethyl sulfoxide (DMSO) at a stock concentration of 10mM and 
stored at -20oC.  6OHDA (Sigma-Aldrich, St. Louis, MO) was prepared in cold sterile water 
immediately before each use.  NAD+ (Sigma-Aldrich, St. Louis, MO) was dissolved in sterile 
water at a stock concentration of 50mM and stored at -80oC.  Colchicine (Sigma-Aldrich, St. 
Louis, MO) was prepared in sterile water at a stock concentration of 1mM and stored at 4oC.  All 
drugs were used at concentrations as indicated in the text and handled while minimizing light 
exposure. 
3.4 CELL TOXICITY ASSAYS 
3.4.1 Lactate Dehydrogenase (LDH) Release Assay 
Cells were plated in a black, clear-bottom 96-well plate and treated with 6OHDA for varying 
dosage and time.  LDH (lactate dehydrogenase) release was measured using the CytoTox-ONE 
Homogeneous Membrane Integrity Assay per the protocol provided by the manufacturer 
(Promega, Madison, WI).  Dead or dying cells with damaged membranes release LDH into the 
culture medium, which is involved in a series of enzymatic reactions to produce a fluorescent 
product that is proportional to the amount of LDH present.  Spectramax M2 plate reader was 
utilized to read the fluorescent signal (Molecular Devices, Sunnyvale, CA).  Percent cytotoxicity 
was calculated by the following formula: 100 x [(Experimental – Medium Background) / 
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(Maximum LDH release – Medium Background)].  Maximum LDH release was determined by 
treatment of cells with lysis buffer as per manufacturer’s protocol.   
3.4.2 MTS Assay 
Cells were plated in a clear 96-well plate and treated with 6OHDA for varying dosage and time.  
Cell toxicity resulting from 6OHDA was determined via the CellTiter 96 Aqueous Non-
Radioactive Cell Proliferation Assay (MTS) as per the manufacturer’s protocol (Promega, 
Madison, WI).  MTS is a salt that is reduced by dehydrogenase enzymes in metabolically active 
cells into a formazan product that has absorbance at 490nm.  The amount of absorbance is 
directly proportional to the number of cells.  Since 6OHDA oxidation itself can cause media 
color changes, a parallel 96-well plate with only media was similarly treated with 6OHDA and 
the absorbance readings were used to correct for any color changes resulting from 6OHDA itself.  
Spectramax M2 plate reader was utilized to read the colorimetric signal.      
3.5 IMMUNOCYTOCHEMISTRY 
For EB1 protein detection, media was removed from the cells, -20oC methanol (Fisher Scientific, 
Pittsburgh, PA) was added, and cells were placed at -20oC for 5min.  For all other fixations, cells 
were first washed with Dulbecco’s Phosphate Buffered Saline (DPBS) (Gibco, Grand Island, 
NY) and fixed in 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO) prepared in phosphate 
buffered saline (PBS) for 30min at room temperature.  After PBS washes, cells were 
permeabilized with 0.1% Triton X-100 (Fisher Scientific, Pittsburgh, PA) in PBS for 20min and 
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then blocked with a commercial blocking buffer (SuperBlock, Thermo Scientific, Rockford, IL) 
for 1hr at room temperature to decrease non-specific antibody binding.  After PBS washes, cells 
were incubated in primary antibody overnight at 4oC or 1hr at room temperature.  Secondary 
antibody was used at a dilution of 1:1000 for 1hr at room temperature.  Both primary and 
secondary antibodies were diluted in a commercial antibody diluent (BioGenex, Fremont, CA).  
After further PBS washes, cells were imaged on an Olympus IX71 inverted microscope.  Primary 
antibodies used: α-tubulin (1:5000; Sigma-Aldrich, St. Louis, MO), acetylated-tubulin (1:1000; 
Sigma-Aldrich, St. Louis, MO), EB1 (1:500; BD Biosciences, San Jose, CA), FLAG (1:5000; 
Sigma-Aldrich, St. Louis, MO), HDAC6 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), 
and SIRT2 (1:1000; Sigma-Aldrich, St. Louis, MO).  Secondary antibodies used: Alexa Fluor-
488 (Invitrogen, Carlsbad, CA) and Cy3 (Jackson ImmunoResearch Laboratories, West Grove, 
PA).   
3.6 IMMUNOBLOTTING 
Cells were washed in DPBS and then collected via a cell scraper in scraping buffer: 25mM 
HEPES pH 7.5 (Research Organics, Cleveland, OH), 50mM NaCl (Fisher Scientific, Pittsburgh, 
PA), 5mM EDTA (Fisher Scientific, Pittsburgh, PA), 2mM PMSF (Acros Organics, Geel, 
Belgium), and 1mM sodium orthovanadate (Sigma-Aldrich, St. Louis, MO).  Cells were 
centrifuged at 1000 x g for 5min and lysed in lysis buffer: 25mM HEPES pH 7.5, 150mM NaCl, 
5mM EDTA, 10% glycerol (Acros Organics, Geel, Belgium), 1% Triton X-100, 1mM sodium 
orthovanadate, and 1:100 dilution of protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO).  
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Cells were lysed on ice for at least 30min, centrifuged at 14,000 x g for 15min, and the 
supernatant was collected and stored at -80oC. 
 Protein concentration was determined using the Coomassie Plus (Bradford) Protein Assay 
(Thermo Scientific, Rockford, IL).  25 – 30ug of total protein was separated by SDS-PAGE 
using the Bio-Rad (Hercules, CA) gel running system and transferred to a PVDF (Millipore, 
Billerica, MA) membrane using a Trans-Blot SD Semi-Dry Transfer Cell apparatus (Bio-Rad, 
Hercules, CA).  The membrane was then blocked with 5% milk in PBST (PBS with 0.3% Tween 
20 [Fisher Scientific, Pittsburgh, PA]) for 1hr at room temperature.  After 3 PBST washes, the 
membrane was incubated in primary antibody (diluted in PBST with 1% bovine serum albumin 
and 0.05% sodium azide) at 4oC overnight.  After 3 PBST washes, the membrane was incubated 
in horseradish peroxidase-conjugated secondary antibody (GE Healthcare, Piscataway, NJ) 
diluted (1:5000) in 5% milk for 1hr at room temperature.  The membrane was washed 3 times in 
PBST and developed using SuperSignal West Pico (Thermo Scientific, Rockford, IL).  Primary 
antibodies used:  acetylated tubulin (1:10:000; Sigma-Aldrich, St. Louis, MO), α-tubulin 
(1:5:000; Sigma-Aldrich, St. Louis, MO), GAPDH (1:10:000; Abcam, Cambridge, MA), 
HDAC6 (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA), and SIRT2 (1:500; Sigma-
Aldrich, St. Louis, MO).  ImageJ (NIH) was utilized for densitometry. 
3.7 IMMUNOPRECIPITATION & DEACETYLASE ACTIVITY ASSAY 
Cells were grown in 10cm dishes to at least 80% confluency, washed with DPBS, and then lysed 
directly on the plate with lysis buffer: 50mM Tris HCl pH 8.0, 137mM NaCl, 2.5mM EDTA pH 
8.0, 1% Triton X-100, 1mM sodium orthovanadate, and 1:100 dilution of protease inhibitor 
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cocktail.  Cells in lysis buffer were scraped and allowed to lyse for at least 30min at 4oC with 
constant agitation.  Lysates were centrifuged at 14,000 x g for 15min.  Supernatant was collected 
and protein concentration was determined via a Bradford Assay.  Approximately 1mg of protein 
was added to 50uL of Protein A-Agarose beads (Sigma-Aldrich, St. Louis, MO) that had been 
previously washed 5 times in 500uL lysis buffer.  2 – 3ug of IgG (Vector Laboratories, 
Burlingame, CA) depending on if it’s a control for HDAC6 or SIRT2, 2ug of HDAC6, or 3ug of 
SIRT2 antibodies were then added to the lysate/bead mixture.  The immunoprecipitation was 
carried out overnight at 4oC with constant agitation.  The following day, the beads were collected 
at 0.1 x g for 5min and washed 3 times in lysis buffer with protease inhibitors and twice in 
HDAC Assay Buffer that is provided with the kit.  At each wash, beads were incubated in 500uL 
of buffer for 5min at 4oC with constant agitation.  After the final wash and centrifugation, nearly 
all of the buffer was carefully removed.   
To assess the activity of the pulled-down deacetylase, a Fluor-de-Lys-Green HDAC 
fluorometric activity assay kit was utilized (Enzo Life Sciences, Farmingdale, NY) as per the 
manufacturer’s protocol.  Briefly, 100μM of the Fluor-de-Lys-Green substrate that contains an 
acetylated lysine side chain was added to the bead/antibody/enzyme mixture and the reaction 
was carried out for 15min to 1hr at 37oC with constant agitation.  For SIRT2 activity, 500μM 
NAD+ was also added to the reaction.  Once the reaction was complete, 50uL of the reaction was 
added to an opaque, white, ½-volume 96-well plate and 50uL of a Fluor-de-Lys Developer 
solution containing 2μM Trichostatin A (for HDAC6 inhibition; final concentration after 
addition was 1μM) or 2μM nicotinamide (for SIRT2 inhibition; final concentration after addition 
was 1μM) was added.  The plate was incubated at room temperature for at least 20min and the 
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fluorescent signal was read (excitation: 485nm; emission: 530nm) using a Spectramax M2 plate 
reader.  
After completion of the deacetylase reaction, beads were washed 3 times in 500uL lysis 
buffer as before.  After the final wash and centrifugation, nearly all of the lysis buffer was 
carefully removed and 40uL of SDS-PAGE sample buffer was added (66mM Tris-HCL pH 6.8 
[Fisher Scientific, Pittsburgh, PA], 26.3% glycerol, 2.1% SDS [Bio-Rad, Hercules, CA], 0.01% 
bromophenol blue [Fisher Scientific, Pittsburgh, PA], and 50mM DTT [Sigma-Aldrich, St. 
Louis, MO]).  The beads in sample buffer were boiled for 5min, centrifuged, and the supernatant 
was collected and stored at -80oC.           
3.8 NAD+ / NADH QUANTIFICATION 
To determine levels of NAD+ in cells, a NAD+/NADH Quantitation Kit was utilized (BioVision, 
Milpitas, CA).  Cells were washed in DPBS, trypsinized (BioWhittaker, Walkersville, MD), and 
collected in media.  Cell number was determined using trypan blue exclusion (Thermo Scientific, 
Rockford, IL).  2 million cells were pelleted at 1000 x g for 5min and the pellet was washed 
twice with DPBS.  400uL of Extraction Buffer was added and two freeze/thaw cycles (20min on 
dry-ice and 15min at room temperature) were carried out to extract NAD+ and NADH.  The 
sample was vortexed for 10sec and centrifuged at 14,000 rpm for 5min.  30uL of the sample was 
removed at this point for protein assay.  The remaining sample was filtered through a 10kD 
molecular weight cut off filter (Abcam, Cambridge, MA) to remove any enzymes that could 
consume NAD+ or NADH.  The sample was stored frozen at -80oC until use.  For determination 
of NAD+ and NADH (NADt), 50uL of the extracted sample was transferred to a 96-well plate in 
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duplicates.  To determine NADH, the extracted sample was incubated at 60oC for 30min to 
decompose NAD+ but leaving NADH intact.  50uL of the decomposed sample was then 
transferred to the 96-well plate in duplicates.  To these samples, 100uL of buffer containing 
enzymes that carry out the cycling reaction and 10uL of developer solution were added per the 
manufacturer’s protocol.  The reaction was incubated at room temperature from 1hr to 4hr and 
the absorbance was read at 450nm using a Spectramax M2 plate reader.  To calculate NAD+, the 
value for NADH was subtracted from the value from NADt.  A blank that does not contain any 
NAD+ or NADH was used for background subtraction.  A BCA (bicinchoninic acid) protein 
assay (Thermo Scientific, Rockford, IL) was carried out on the samples saved prior to filtration 
per the manufacturer’s protocol.  Absorbance values of NAD+ and NADH were normalized to 
protein concentration.          
3.9 LIVE CELL IMAGING OF MT DYNAMICS 
To study MT dynamics, media on cells expressing fluorescently-tagged EB3 was removed and 
37oC DPBS, which contains glucose, was added.  Cells were then transferred to an Olympus 
IX71 inverted microscope with a 60X oil objective and a heated stage set to 37oC (Warner 
Instruments, Hamden, CT).  Cells with low expression of EB3-GFP / EB3-mCherry, e.g. 
showing a clear comet-like pattern, were followed since it has been shown that low-level 
expression of such proteins does not affect the dynamic behavior of MTs [185].  Images were 
taken every 5sec at an exposure time of 500ms (EB3-GFP) or 1sec (EB3-mCherry; less bright 
than GFP).  A neutral density filter that reduces light intensity by 50% was used for all live cell 
imaging to minimize any potential damage of excessive ultraviolet light exposure.   
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3.10 IMAGE ANALYSIS 
Neurite length was measured in GFP expressing cells via the ImageJ software (NIH).  At least 50 
neurites were quantified for each group of an experiment (per replicate).  EB comet length was 
measured in cells that were imaged at the same exposure time and, using ImageJ, thresholded 
with the same parameters to minimize the background noise and highlight the EB comets.  The 
longest distance between two points (Feret’s diameter) was determined for each comet.  At least 
10 comets per cell and at least 5 cells were analyzed for each group of an experiment (per 
replicate).  For MT growth rate measurements, EB3 comets that could be followed for at least 
three consecutive frames were measured using the MTrackJ plugin for ImageJ [186].  For 
measurements of pauses/retractions, the number of comet dimming events, time elapsed in each 
dimming event, and time between two dimming events was determined.  For measurements of 
growth rate and pauses/retractions, at least 5 comets per cell and at least 5 cells were analyzed 
for each group of an experiment (per replicate).       
3.11 STATISTICAL ANALYSIS 
Student’s t test was used for comparison of means between two groups.  One-way analysis of 
variance (ANOVA) followed by post-hoc Tukey HSD test was used for multiple comparisons.  
A p-value < 0.05 was considered statistically significant. 
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4.0  RESULTS 
4.1 6OHDA MODEL OF OXIDATIVE STRESS 
For this study, human SH-SY5Y cells were utilized.  These cells were originally derived from 
SK-N-SH cells that were recovered from a human metastatic neuroblastoma tissue [187].  SH-
SY5Y cells have been widely used in the field of PD given that they possess many dopaminergic 
characteristics [188,189].  These cells express tyrosine hydroxylase, dopamine-β-hydroxylase, 
and the dopamine transporter [188,190,191].  Furthermore, SH-SY5Y cells can be differentiated, 
e.g. with retinoic acid, to a more mature neuronal phenotype, biochemically as well as 
morphologically.  Upon differentiation, cells stop proliferation, various neuronal markers are 
expressed, and long neurites are formed [188,189,192].  Hence, given these properties of SH-
SY5Y cells, they have served as an important model of dopaminergic neurons in PD.       
It was first important to carry out cell viability assays to determine the concentration and 
length of 6OHDA treatment that do not cause cellular toxicity.  Previous work from the lab as 
well as my studies with nuclear transport (see Appendix) had suggested that 150μM of 6OHDA 
was an effective pre-lethal dose.  Therefore, a time course of 150μM 6OHDA in undifferentiated 
SH-SY5Y cells was carried out to determine if there was cellular toxicity (Fig. 2).  Since 
6OHDA, particularly at high concentrations, can change the color of the media, there were 
concerns of interference with colorometric assays such as the MTS assay.  Hence, a 
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fluorescence-based LDH release assay was performed.  As seen in Figure 2, no significant 
toxicity was observed until 6hr after 150μM 6OHDA treatment.  For subsequent experiments 
utilizing this pre-lethal dose, treatment times of ≤ 4hr were used.      
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Figure 2:  Cell Viability in Response to Pre-lethal 6OHDA 
LDH release assay showed no evidence of toxicity until 6hr of 150μM 6OHDA treatment in undifferentiated SH-
SY5Y cells.  Mean +/- SEM, *p < 0.05 vs. Cont.  Compiled from 3 independent experiments. 
 
It was also of great interest to develop a sub-lethal oxidative stress injury model where 
the effects of more long-term oxidative stress, as is the case in aging and neurodegenerative 
diseases such as PD, can be studied.  For these studies, examining neurite integrity was of 
particular interest and hence SH-SY5Y cells were differentiated with retinoic acid (RA) as 
described in the Methods Section.  Viability assays were carried out in differentiated cells treated 
with varying concentrations of 6OHDA over a time of 24hr – 72hr.  First, over the course of 
24hr, the effects of various concentrations of 6OHDA were examined via both LDH release and 
MTS assays (Fig. 3A & 3B).  Concentrations ≤ 30μM did not cause cell death, which was a 
consistent observation in both toxicity assays.  Allowing cells to grow for another 48hr after a 
24hr 6OHDA treatment also did not lead to cell death for doses ≤ 30μM, suggesting that the cells 
were not irreversibly damaged (Fig. 3C).  Furthermore, cells were treated every 24hr for a total 
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of 72hr with various concentrations of 6OHDA and again doses ≤ 30μM did not cause cell death 
(Fig. 3D).  Only the MTS assay was carried out for Fig. 3C & 3D because media change was 
required for these treatment paradigms, making the LDH release assay incompatible since any 
LDH released into the media would have been washed away with the media changes.    
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Figure 3:  Cell Viability in Response to Sub-lethal 6OHDA 
Differentiated SH-SY5Y cells were treated with various concentration of 6OHDA from 24hr to 72hr.  (A & B) LDH 
release and MTS assays – no evidence of toxicity for 6OHDA concentrations ≤ 30μM (24hrs) was observed.  (C) 
MTS assay – cells were treated for 24hr with 15μM to 60μM 6OHDA and then allowed to recover for another 48hr.  
No significant cell loss was observed for concentrations ≤ 30μM.  (D) MTS assay – cells were treated three times 
(every 24hr) with varying concentrations of 6OHDA and no significant cell loss was observed for concentrations ≤ 
30μM.  Mean +/- SEM, *p < 0.05 or nsp > 0.05 vs. Cont.  Compiled from 3 independent experiments. 
 
In summary, for studying the effects of pre-lethal 6OHDA, undifferentiated SH-SY5Y 
cells and 150μM 6OHDA with treatment times less than 4hr were used.  For studying the effects 
of sub-lethal 6OHDA, RA-differentiated SH-SY5Y cells and 30μM 6OHDA every 24hr for a 
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total of 72hr (3 total treatments) were used.  Figure 4 summarizes the two models and also shows 
the morphological change that occurs upon differentiation. 
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Figure 4:  Pre-lethal and Sub-lethal 6OHDA Models 
Two 6OHDA injury models are used in this study.  Undifferentiated cells are used for pre-lethal treatments (150μM; 
≤ 4hr) and retinoic acid (RA)-differentiated cells are used for sub-lethal treatments (30μM; 72hr total treatment time; 
every 24hr).  Upon differentiation, a prominent neuritic process, sometimes two, extends from the cell body.  N = 
nucleus. 
4.2 EFFECT OF 6OHDA ON MT DYNAMICS 
A couple of studies have suggested that 6OHDA could disrupt MT function.  In 1979, Tomlinson 
et al. showed that noradrenergic preterminal fibers of 6OHDA treated rats show disorganized or 
absent MT staining [193].  In 1986, Davison et al. showed that high (millimolar) concentrations 
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of 6OHDA reduced the polymerization rate of tubulin in vitro [64].  These studies involved high 
concentrations of 6OHDA and did not study MT function in detail.  With advancement in 
molecular biology and imaging technology since the publication of these initial reports, one can 
now examine detailed MT function in individual cells. 
4.2.1 EB Comets 
A major method to examine MT function in cells is through the study of +TIPs.  When +TIPs, 
such as EBs, are visualized via transfection of a fluorescently-tagged protein or immunochemical 
detection of an endogenous protein, a “comet” like pattern is observed (Fig. 5).  In Figure 5, 
endogenous EB1 comets are visualized by immunofluorescence.  This unique pattern is thought 
to be due to disappearance of +TIP binding sites as the MT grows – leading to regions of low 
(comet tail) and high (comet head) densities of these proteins [84].    
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Figure 5:  Anatomy of an EB Comet 
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Methanol-fixed SH-SY5Y cells were immunostained for endogenous EB1.  Comet-like pattern is observed with a 
head (high EB density) and a tail (low EB density).  The rest of the MT lattice is not visible.  (-) indicates the minus-
end of the MT.   
4.2.2 Tracking MTs in Live Cells 
The effects of pre-lethal and sub-lethal 6OHDA injury on MT dynamics were examined using 
fluorescently-tagged EB3.  The use of fluorescently-tagged +TIPs, such as EBs, have been 
extensively characterized for the study of MT dynamics in living cells [177,185,194].  Since 
these proteins bind to the growing (plus) ends of MTs, they allow one to determine the rate of 
MT growth in cells.  Figure 6A shows the comet-like fluorescence for EB3-GFP in a neurite of a 
differentiated SH-SY5Y cell.  A few growing MTs (two are indicated by the arrows) can be seen 
moving to the right, which is towards the growth cone (not seen in the images). 
EBs, along with other +TIPs, only bind to the MTs when they are growing.  Therefore, 
during MT pauses or retractions, the MT ends are not as bright or invisible when using EB3-GFP 
to visualize them.  As seen in Figure 6B, when the MTs pause or retract, the intensity of the 
comet-like fluorescence of EB3-GFP decreases.  If the MT in this example had paused for a 
longer period of time, all of the EB3-GFP at the MT plus-end would have been lost and the MT 
would no longer be visible.  As the MT beings to grow again, the fluorescent intensity of the 
EB3-GFP comet is again increased.  Given this feature of +TIPs, one can study other important 
aspects of MT dynamics besides growth rate, such frequency and length of MT 
pauses/retractions.  Since it is difficult at times to differentiate between a pause and a retraction, 
each “dimming” event will be referred to as a pause and/or retraction event, or a “P/R” event, in 
subsequent studies.     
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Figure 6:  Studying MT Dynamics in Live Cells 
SH-SY5Y cells were transfected with an expression plasmid for EB3-GFP.  (A)  A comet-like pattern of EB3-GFP 
is seen and the comets are shown (arrows) moving to the right (towards growth cone; not seen in images).  (B) An 
example of a “dimming” event where the EB3-GFP comet loses its fluorescent intensity (0:15 to 0:20), suggesting 
MT pausing or retraction.  Return to the growth phase is noted by the increase in the fluorescent intensity and the 
forward movement of the comet.  Images were taken at 5sec intervals.  
 
4.2.3 Effect of 6OHDA on MT Growth Rate 
Using EB3-GFP as a tool to study MT dynamics in live cells, the effects of 6OHDA-induced 
oxidative stress on MT growth rate was examined.  In the pre-lethal 6OHDA model, a significant 
decrease in MT growth rate was observed (Fig. 7A).  With a low-dose and long-term exposure to 
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6OHDA (sub-lethal), a less dramatic but still statistically significant decrease in MT growth rate 
was observed (Fig. 7B).  For the sub-lethal injury model, MTs along the neurite, not the cell 
body, were examined since neuritic biology is of particular interest in this study. 
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Veh. Cont. 30μM 72hr 6OHDA
Av
er
ag
e 
Ve
lo
ci
ty
 (μ
m
/s
ec
)
*
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Veh. Cont. 150μM 4hr 6OHDA
Av
er
ag
e 
Ve
lo
ci
ty
 (μ
m
/s
ec
)
*
A BPre-lethal Sub-lethal
 
Figure 7:  6OHDA Reduces MT Growth Rate 
(A) Undifferentiated SH-SY5Y cells expressing EB3-GFP were treated with 150μM 6OHDA for 4hr (Pre-lethal).  
Oxidatively-stressed cells show reduced MT growth rates.  (B)  Differentiated SH-SY5Y cells expressing EB3-GFP 
were treated with 30μM 6OHDA for 72hr (treatment every 24hr) (Sub-lethal).  MTs along the length of the neurite 
in 6OHDA-treated cells show reduced growth rates.  Mean +/- SEM, *p < 0.05 vs. Veh. Cont.  n = 150 – 200 EB3-
GFP comets per group compiled from 3 independent experiments.  
4.2.4 Effect of 6OHDA on MT Pauses / Retractions 
Although a reduction in MT growth rate was observed in cells treated with sub-lethal doses of 
6OHDA, the effect was more subtle than that observed in the pre-lethal condition.  As previously 
mentioned, there are other aspects of MT dynamics that are just as important, such as MT pauses 
and retractions.  Hence, in the sub-lethal oxidative stress model, MTs along the length of the 
neurite were also analyzed for parameters such as frequency of MT pauses/retractions (P/R 
event), time spent pausing/retracting, and time elapsed between pauses/retractions.  As 
mentioned above, an EB3-GFP “dimming” event is referred to as a “P/R” event.  With sub-lethal 
6OHDA stress, an increase in the frequency of P/R events is observed (Fig. 8A).  6OHDA 
treatment caused individual MTs to pause/retract more over a given period of time as seen in 
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Figure 8B – a lower percentage of 0 and 1 P/R events and a greater percentage of 2 and 3+ P/R 
events is observed.  The amount of time that elapses between two P/R events was reduced in 
6OHDA treated cells (Fig. 8C).  If there is an increase in number of events per time, it would 
make sense that the time between each event would be reduced.  However, this is the case only if 
the time elapsed in each P/R event is the same, which is in fact the case with sub-lethal 6OHDA 
injury (Fig. 8D).  Hence, significant alterations in many aspects of MT dynamics, including MT 
growth rate and frequency of pauses/retractions, are observed with sub-lethal oxidative stress.  
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Figure 8:  Sub-lethal 6OHDA Alters MT Pauses/Retractions  
SH-SY5Y cells were treated with sub-lethal 6OHDA and MT dynamics was examined.  (A & B)  An increase in the 
frequency / number of MT pauses and retractions (P/R) is seen after treatment.  (C)  The average amount of time 
between two P/R events is reduced with treatment; however the amount of time spent in an individual P/R event is 
not altered (D).  Mean +/- SEM, *p < 0.05 or nsp > 0.05 vs. Veh. Cont.  n = 100 – 200 EB3-GFP comets per group 
compiled from 3 independent experiments. 
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4.3 EFFECT OF 6OHDA ON END BINDING PROTEINS 
4.3.1 Effect of Pre-lethal 6OHDA on EB1 Comet Length 
In addition to studying MT dynamics in live cells expressing EB3-GFP, the effects of 6OHDA 
on endogenous EBs were also studies.  As discussed previously, EBs are an important group of 
+TIPs as they play a key role in the regulation of MT dynamics.  Interestingly, the length of the 
EB comet is positively correlated with MT growth rate [175-177].  Hence, this feature allows 
one to indirectly determine MT growth rate in cells based on the EB comet length.  With pre-
lethal 6OHDA injury, cells showed decreased EB1 comet length (Fig. 9A & 9B).  This result is 
in agreement with reduced MT growth velocities seen in live cells and serves as another way to 
confirm that 6OHDA has a significant effect on MT dynamics.   
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Figure 9:  Pre-lethal 6OHDA Reduces EB1 Comet Length 
SH-SY5Y cells treated with a pre-lethal dose of 6OHDA were fixed and immunostained for endogenous EB1.  (A)  
Representative images of control and 6OHDA treated cells showing reduction in comet length.  (B)  Quantification 
of comet length shows a reduction with 6OHDA treatment.  Mean +/- SEM, *p < 0.05 vs. Veh. Cont.  n = 200 – 300 
EB1 comets per group compiled from 3 independent experiments. 
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4.3.2 Effect of Sub-lethal 6OHDA on EB1 Levels 
The effects of sub-lethal 6OHDA injury on EB1 along the length of the neurite was also 
examined (Fig. 10).  A more punctate pattern of EB1 fluorescence is observed along the neurite 
in control cells, making comet length analysis more difficult and possibly less meaningful (Fig. 
10A).  However, the levels of EB1 can be accurately assessed and can also provide very valuable 
information about MT dynamics.  As can be seen in the representative images in Figure 10A, 
sub-lethal 6OHDA decreased EB1 staining along the length of the neurite.  Western blot analysis 
of total cellular EB1 levels showed a reduction with 6OHDA treatment, which confirms the 
immunocytochemical analysis (Fig. 10B).       
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Figure 10:  Sub-lethal 6OHDA Reduces EB1 Levels 
SH-SY5Y cells were treated with sub-lethal 6OHDA and EB1 levels were analyzed via immunocytochemistry and 
Western blotting.  (A)  Two sets of representative images are shown where reduced EB1 staining is noted along the 
length of the neurite in 6OHDA treated cells.  (B)  Western blot of total cellular EB1 levels shows a reduction with 
6OHDA treatment.  Mean +/- SEM, *p < 0.05 vs. Veh. Cont.  Compiled from 3 independent experiments. 
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4.4 EFFECT OF 6OHDA ON THE TOTAL MT NETWORK   
Given the significant impact of 6OHDA-induced oxidative stress on MT dynamics, it was of 
interest to determine if the overall MT network was affected in treated cells.  Neither pre-lethal 
nor sub-lethal 6OHDA treatment altered the overall MT organization in cells as determined by 
immunostaining for α-tubulin (Fig. 11).        
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Figure 11:  6OHDA Does Not Alter Overall MT Organization 
SH-SY5Y cells treated with pre-lethal (A) or sub-lethal (B) 6OHDA were fixed and immunostained for α-tubulin.  
No significant alterations in the overall organization of MTs were noted.  Representative images of 3 independent 
experiments.   
 
The levels of total α-tubulin were also examined in 6OHDA treated cells.  Neither pre-
lethal nor sub-lethal 6OHDA treatment caused a significant change in cellular α-tubulin levels 
(Fig. 12A & 12B).  Together with the immunocytochemical data, the results suggest more 
specific alterations in MT dynamics as opposed to gross alterations in the MT network.   
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Figure 12:  6OHDA Does Not Alter α-Tubulin Levels 
Total α-tubulin levels were examined in SH-SY5Y cells treated with pre-lethal (A) or sub-lethal (B) 6OHDA.  
6OHDA did not cause any significant alterations in levels of α-tubulin.  Mean +/- SEM, nsp > 0.05 vs. Veh. Cont.  
Compiled from 3 independent experiments. 
4.5 EFFECT OF 6OHDA ON TUBULIN ACETYLATION 
In addition to +TIPs, tubulin post-translational modifications are another major mechanism by 
which MT function is regulated.  One such modification is tubulin acetylation, which not only 
serves as maker of the stable pool of MTs but has been shown to regulate binding of MAPs and 
MT dynamics.  Furthermore, the PD toxin MPP+ has been shown alter the tubulin acetylation 
levels [154].  Hence, the effect of 6OHDA-induced oxidative stress on tubulin acetylation levels 
was also examined in this study.        
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4.5.1 Detection of Acetylated MTs 
The acetylated tubulin antibody, which detects acetylation at Lys-40 of α-tubulin, used in this 
study has been extensively utilized and validated in the MT field.  Nonetheless, this antibody 
was first validated for its ability to specifically detect tubulin acetylation for this study.  SH-
SY5Y cells were treated with colchicine (1μM; 1hr), a MT depolymerizing agent, and acetylated 
tubulin was detected by immunocytochemical (Fig. 13A) and Western blot analyses (Fig. 13B).  
As can be seen via immunocytochemistry, acetylated MTs are dense around the centrosome from 
which fiber-like processes emanate and minimal acetylated MTs are seen at the cell periphery, 
where more dynamic MTs are found (Fig. 13A).  A reduction in tubulin acetylation levels was 
observed with colchicine treatment as expected – confirming that acetylated tubulin can be 
specifically detected. 
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Figure 13:  Detection of Acetylated MTs 
SH-SY5Y cells were treated with the MT depolymerizing agent colchicine (1μM; 1hr) and immunostained (A) or 
Western blotted (B) for acetylated tubulin.  A reduction in the level of acetylated tubulin was seen with colchicine 
treatment.   
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4.5.2 Effect of 6OHDA on Levels of Acetylated MTs 
The effects of pre-lethal and sub-lethal doses of 6OHDA on acetylation of MTs were examined 
in SH-SY5Y cells via Western blot analysis.  A significant increase in levels of acetylated 
tubulin was observed after 6OHDA treatment (Fig. 14).  The effect was more prominent after a 
pre-lethal injury (Fig. 14A) as compared to a sub-lethal injury (Fig. 14B).   
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Figure 14:  6OHDA Increases MT Acetylation 
SH-SY5Y cells were treated with pre-lethal (A) or sub-lethal (B) 6OHDA and levels of tubulin acetylation were 
examined via Western blot analysis.  A significant increase in tubulin acetylation was observed in treated cells.  
Mean +/- SEM, *p < 0.05 vs. Veh. Cont.  Compiled from 3 independent experiments. 
4.6 EFFECT OF 6OHDA ON NEURITE LENGTH 
One of the earliest changes seen in neurodegenerative diseases, such as PD, is the degeneration 
of axons [4].  MTs play a key role in the development and maintenance of axons / neuritic 
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processes and 6OHDA-induced oxidative stress significantly affects MT function.  Hence, the 
effect of sub-lethal oxidative stress, which more closely mimics the injury that occurs in PD, on 
neurite integrity was examined.  Differentiated SH-SY5Y cells expressing GFP were treated with 
sub-lethal 6OHDA, which resulted in a reduction of neurite length (Fig. 15).  Hence, sub-lethal 
6OHDA injury was able to reproduce a very important aspect of neuronal degeneration that is 
seen in PD.       
Veh. Cont.
30μM 72hr 
6OHDA
0
20
40
60
80
100
120
140
Veh. Cont. 30μM 72hr 6OHDA
N
eu
rit
e 
Le
ng
th
 (%
 C
on
t)
*
20μm
20μm
 
Figure 15:  Sub-lethal 6OHDA Reduces Neurite Length 
Differentiated SH-SY5Y cells were transfected with GFP and treated with sub-lethal 6OHDA.  A significant 
reduction in neurite length was observed with 6OHDA treatment.  Mean +/- SEM, *p < 0.05 vs. Veh. Cont.  n = 150 
– 200 cells per group compiled from 3 independent experiments.  
4.7 EFFECT OF 6OHDA ON TUBULIN DEACETYLASES 
Given that tubulin PTMs can affect many aspects of MT function, the mechanism(s) by which 
such a significant change in tubulin acetylation was occurring in 6OHDA treated cells was then 
examined.  Alteration in tubulin acetylation levels suggests the involvement of tubulin acetylases 
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and/or deacetylases.  As previously discussed, tubulin acetylases have only been recently 
identified and not much is known about their regulation.  However, many studies have examined 
in detail the tubulin deacetylases, HDAC6 and SIRT2.  Interestingly, oxidative stressors, e.g. 
H2O2 and cigarette smoke, has been linked to altered localization, levels, and/or activity of 
various HDACs, e.g. HDAC1, HDAC2, HDAC4, and SIRT1, in a variety of models [195-201].  
Given the structural similarities of the deacetylase domain between the various classes of 
HDACs, it is possible that 6OHDA-induced oxidative stress may affect HDAC6 and/or SIRT2 
function.  Hence, the effect of 6OHDA on tubulin deacetylases was studied by examining their 
subcellular localization, protein levels, and enzymatic activity.   
4.7.1 Effect of 6OHDA on HDAC6 and SIRT2 Subcellular Localization 
HDAC6 and SIRT2 are cytoplasmic proteins but have been shown under certain conditions to be 
present in the nucleus.  Upon differentiation of B16 mouse melanoma cells by butyrate where 
cell cycle is arrested, a small amount of HDAC6 can be found in the nuclear fraction [124].  For 
SIRT2, a very small fraction is also found in the nucleus in HeLa and 293T cells [138,143].  
Both proteins contain a nuclear export signal that helps maintain their predominant cytoplasmic 
localization.  Given the possibility that HDAC6 or SIRT2 can be found in the nucleus, the effect 
of 6OHDA on their subcellular localization was examined.   
 SH-SY5Y cells were treated with a pre-lethal dose of 6OHDA and endogenous HDAC6 
was visualized via immunocytochemistry (Fig. 16A).  A complete cytoplasmic localization of 
HDAC6 was observed and treatment with pre-lethal 6OHDA did not cause a change in its 
subcellular distribution (Fig. 16A).  In addition, to confirm the results of endogenous HDAC6, a 
FLAG-tagged HDAC6 was also transfected in cells and detected via anti-FLAG antibody (Fig. 
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16A; lower panel).  Overexpressed HDAC6 also showed a cytoplasmic localization which did 
not change with pre-lethal 6OHDA treatment.  Endogenous HDAC6 localization was then 
examined in differentiated SH-SY5Y cells treated with sub-lethal 6OHDA (Fig. 16B).  As with 
pre-lethal 6OHDA, a cytoplasmic localization of HDAC6 was seen in control cells, which did 
not change with 6OHDA treatment.  Hence, no significant alteration in the subcellular 
localization of HDAC6 was seen in either 6OHDA injury models.   
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Figure 16:  6OHDA Does Not Alter the Subcellular Localization of HDAC6 
(A)  Undifferentiated SH-SY5Y cells were treated with a pre-lethal dose of 6OHDA.  Endogenous (αHDAC6) and 
overexpressed HDAC6 (αFLAG) were detected via immunocytochemistry.  No significant change in the subcellular 
localization of HDAC6 was observed.  (B)  Endogenous HDAC6 was detected in differentiated SH-SY5Y cells and 
no change in its subcellular localization was observed after sub-lethal 6OHDA.  Two separate images are overlaid 
(marked by the dotted white line), one with the cell body in focus and one with the neurite in focus.  Representative 
images of 3 independent experiments are shown. 
 
Similar studies were also carried out for SIRT2 (Fig. 17).  SH-SY5Y cells were treated 
with a pre-lethal dose of 6OHDA and endogenous SIRT2 was visualized via 
immunocytochemistry (Fig. 17A).  A cytoplasmic localization of SIRT2 was observed (no 
nuclear SIRT2 was ever seen in these cells) and treatment with pre-lethal 6OHDA did not cause 
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a change in its subcellular localization (Fig. 17A).  Furthermore, overexpressed SIRT2 also 
showed a cytoplasmic localization which did not change with pre-lethal 6OHDA treatment (Fig. 
17A; lower panel).  Endogenous SIRT2 localization was also examined in differentiated SH-
SY5Y cells treated with sub-lethal 6OHDA (Fig. 17B).  As with pre-lethal 6OHDA, a 
cytoplasmic localization of SIRT2 was seen in control cells, which did not change with 6OHDA 
treatment.  Hence, as seen with HDAC6, no significant alteration in the subcellular localization 
of SIRT2 was observed after 6OHDA-induced oxidative stress.   
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Figure 17:  6OHDA Does Not Alter the Subcellular Localization of SIRT2 
(A)  Undifferentiated SH-SY5Y cells were treated with a pre-lethal dose of 6OHDA.  Endogenous (αSIRT2) and 
overexpressed SIRT2 (αFLAG) were detected via immunocytochemistry.  No significant change in the subcellular 
localization of SIRT2 was observed.  (B)  Endogenous SIRT2 was detected in differentiated SH-SY5Y cells and no 
change in its subcellular localization was observed after sub-lethal 6OHDA.  Two separate images are overlaid 
(marked by the dotted white line), one with the cell body in focus and one with the neurite in focus.  Representative 
images of 3 independent experiments are shown. 
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4.7.2 Effect of 6OHDA on HDAC6 and SIRT2 Protein Levels 
Endogenous protein levels of HDAC6 and SIRT2 in 6OHDA treated cells were also examined.  
Levels of HDAC6 were not altered in response to either pre-lethal or sub-lethal 6OHDA (Fig. 
18A & 18B).  Hence, changes in HDAC6 protein levels do not contribute to the increased tubulin 
acetylation that is observed.    
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Figure 18:  6OHDA Does Not Alter HDAC6 Protein Levels 
SH-SY5Y cells were treated with pre-lethal (A) or sub-lethal (B) 6OHDA and HDAC6 protein levels were 
examined via Western blot analysis.  No significant changes in protein levels were detected.  Mean +/- SEM, nsp > 
0.05 vs. Veh. Cont.  Compiled from 3 independent experiments. 
      
For SIRT2, although not statistically significant, pre-lethal dose of 6OHDA caused a 
trend towards a reduction in protein levels (Fig. 19A).  This trend was consistently observed in 
the majority of the replicates.  However, sub-lethal 6OHDA did not significantly alter SIRT2 
protein levels and no consistent pattern was observed despite the quantified results showing a 
trend towards an increase (Fig. 19B).   
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Figure 19:  6OHDA Does Not Alter SIRT2 Protein Levels 
SH-SY5Y cells were treated with pre-lethal (A) or sub-lethal (B) 6OHDA and SIRT2 protein levels were examined 
via Western blot analysis.  No statistically significant changes in protein levels were detected although a consistent 
trend towards reduced SIRT2 levels was seen after pre-lethal treatment.  Mean +/- SEM, nsp > 0.05 vs. Veh. Cont.  
Compiled from 3 independent experiments. 
 
Hence, in the pre-lethal injury model, it is possible that reduced SIRT2 levels contribute 
to an increase in tubulin acetylation.  However, this effect is not statistically significant and 
hence other mechanisms that could explain increased tubulin acetylation levels in both the pre-
lethal as well as the sub-lethal models were explored. 
4.7.3 Effect of 6OHDA on HDAC6 and SIRT2 Deacetylase Activity 
Deacetylase activity of various HDACs has been shown to be sensitive to oxidative stress.  
Hence, the effect of 6OHDA-induced oxidative stress on the deacetylase activity of HDAC6 and 
SIRT2 was examined.  First, immunoprecipitation of endogenous HDAC6 and deacetylase 
activity of the pulled-down protein was examined (Fig. 20).  Figure 20A shows the strong pull-
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down of HDAC6.  Various substrate and developer incubation times were also examined to 
determine the linear range of the enzymatic reaction, which was used for all subsequent 
experiments looking at HDAC6 activity (Fig. 20B).  Pulled-down HDAC6 showed significant 
activity above IgG control (Fig. 20C).   
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Figure 20:  HDAC6 Deacetylase Activity 
(A)  Endogenous HDAC6 was pulled-down in SH-SY5Y cells.  (B)  Activity of HDAC6 was examined at various 
substrate incubation times and with varying developer incubation times.  Times in the linear range were chosen for 
subsequent experiments.  R2 values > 0.99.  AFUs = Artificial Fluorescence Units.  (C) Significant HDAC6 activity 
was seen above IgG control.  Mean +/- SEM, *p < 0.05 vs. IgG.  Compiled from 3 independent experiments.  
 
 HDAC6 was pulled-down from equivalent amount of lysates collected from SH-SY5Y 
cells treated with either pre-lethal or sub-lethal 6OHDA and the deacetylase activity was 
examined.  Fluorescence values of IgG control were subtracted from the HDAC6 activity values 
and percent change was determined.  No significant change in the deacetylase activity of the 
pulled-down enzyme was detected in either of the 6OHDA-induced oxidative stress models (Fig. 
21).  Hence, altered deacetylase activity of HDAC6 does not contribute to the increased level of 
tubulin acetylation that is observed.  
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Figure 21:  6OHDA Does Not Alter HDAC6 Deacetylase Activity 
SH-SY5Y cells were treated with either pre-lethal (A) or sub-lethal (B) 6OHDA and the deacetylase activity of 
pulled-down HDAC6 was examined.  No significant change in enzymatic activity was observed.  Mean +/- SEM, nsp 
> 0.05 vs. Veh. Cont.  Compiled from 3 independent experiments. 
 
 The deacetylase activity of SIRT2 was then examined.  Again, endogenous SIRT2 pull-
down was first confirmed and a linear range of substrate and developer incubation times was 
determined for subsequent studies (Fig. 22A & 22B).   The arrow in Fig. 22A points to a non-
specific band seen only in the IgG lane (likely an IgG heavy chain fragment).  SIRT2 deacetylase 
activity was seen above IgG control (Fig. 22C).  A significant portion of this activity was 
dependent on NAD+ as would be expected for a sirtuin (Fig. 22D).  Although SIRT2 pull-down 
is not as strong (addressed in the Discussion section) as that seen for HDAC6, it does appear to 
be enough to see significant activity above IgG control.  The SIRT2 antibody strongly detects 
SIRT2 at the correct molecular weight via Western blotting and has been confirmed for 
immunoprecipitation by the manufacturer.  However, in the immunoprecipitations done in this 
study, an unknown band in addition to SIRT2 is also observed.  This band is stronger than the 
SIRT2 band that is pulled-down and hence requires follow-up.  A detailed discussion of this 
matter is provided later in the Discussion section.        
 55 
0
20
40
60
80
100
120
140
160
180
200
IgG SIRT2
D
ea
ce
ty
la
se
 A
ct
iv
ity
 (%
 Ig
G
)
*
50
60
70
80
90
100
110
120
130
140
150
IgG IP: SIRT2 IP: SIRT2
D
ea
ce
ty
la
se
 A
ct
iv
ity
 (%
Ig
G
)
(-) NAD+ (+) NAD+
*
IP: SIRT2              IgG
SIRT2
A
B
C
0
5000
10000
15000
20000
25000
30000
0 20 40 60 80
AF
U
s
Substrate Incubation Time (min)
15min
30min
60min
Developer 
Incubation 
Time:
D
 
Figure 22:  SIRT2 Deacetylase Activity 
(A)  Endogenous SIRT2 was pulled-down in SH-SY5Y cells.  Arrow points to a non-specific band in the IgG lane.  
(B)  Activity of SIRT2 was examined at various substrate incubation times and with varying developer incubation 
times.  Times in the linear range were chosen for subsequent experiments.  R2 values > 0.99.  AFUs = Artificial 
Fluorescence Units.  (C) Significant SIRT2 activity was seen above IgG control.  Mean +/- SEM, *p < 0.05 vs. IgG.  
Compiled from 3 independent experiments.  (D)  Deacetylase activity of the pulled-down enzyme is dependent on 
NAD+.  Mean +/- SD, *p < 0.05 as indicated.  
 
 SIRT2 was pulled-down from equivalent amount of lysates collected from SH-SY5Y 
cells treated with either pre-lethal or sub-lethal 6OHDA and the deacetylase activity was 
examined.  As with HDAC6, fluorescence values of IgG control were subtracted from the SIRT2 
activity values and percent change was determined.  For pre-lethal dose of 6OHDA, no 
significant change in the deacetylase activity of the pulled-down enzyme was detected (Fig. 
23A).  However, a significant reduction in the deacetylase activity of SIRT2 after sub-lethal 
injury was observed (Fig. 23B).  Hence, reduced SIRT2 activity could account for the increased 
levels of tubulin acetylation in the sub-lethal oxidative stress injury model.     
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Figure 23:  Sub-lethal 6OHDA Reduces SIRT2 Deacetylase Activity 
SH-SY5Y cells were treated with either pre-lethal (A) or sub-lethal (B) 6OHDA and the deacetylase activity of 
pulled-down SIRT2 was examined.  (A)  For pre-lethal 6OHDA, no significant change in enzymatic activity was 
observed.  (B)  Significant reduction in activity was observed for SIRT2 from cells treated with sub-lethal 6OHDA.  
Mean +/- SEM, *p < 0.05 or nsp > 0.05 vs. Veh. Cont.  Compiled from 3 independent experiments.   
4.8 EFFECT OF 6OHDA ON NAD+ / NADH LEVELS 
Results thus far suggest that reduction in SIRT2 deacetylase activity in the sub-lethal 6ODHA 
injury model could explain the observed increase in levels of tubulin acetylation.  However, only 
a trend towards a reduction in SIRT2 protein level was seen with pre-lethal 6OHDA injury, 
where a very robust increase in levels of tubulin acetylation is observed.  NAD+ is an essential 
co-factor for SIRT2 deacetylase activity and is an important determinant of the redox state of the 
cell.  If 6OHDA-induced oxidative stress alters the levels of NAD+ in the pre-lethal model, it 
could explain how SIRT2 function could be decreased in cells without seeing a decrease in the 
deacetylase activity assay, which is under optimal conditions where NAD+ is provided.  Using 
an enzyme cycling reaction, the levels of NAD+ and NADH were examined in cells treated with 
either pre-lethal or sub-lethal 6OHDA.  First, the linear range of the assay was determined by 
varying the number of cells used for extraction and the reaction incubation time (Fig. 24A).  
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Based on the results, 1 – 2 million cells and a reaction time of 2hr was used for subsequent 
studies.  In addition, cells showed a much higher level of NAD+ than NADH, which is 
biologically valid (Fig. 24B) [202].       
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Figure 24:  Detection of NAD+ and NADH in Cells 
(A)  Linear range of the assay was determined using NAD(t) (combined NAD+ and NADH levels) and 1 – 2 million 
cells and a reaction time of 2hr was used for subsequent studies.  R2 > 0.99 for all conditions except for 4 million 
cells (R2 = 0.96).  (B) NAD+ levels were significantly higher in cells than NADH levels.  OD450 = Absorbance at 
450nm.  Compiled from 3 independent experiments. 
 
 The effect of 6OHDA-induced oxidative stress on NAD+ and NADH levels was then 
examined.  Pre-lethal 6OHDA treatment caused a significant reduction in the levels of both 
NAD+ and NADH (Fig. 25A & 25B).  However, no such reduction was observed after sub-lethal 
injury (Fig. 25C & 25D).  Hence, in the pre-lethal model, reduction in the levels of the essential 
co-factor NAD+ can lead to reduced SIRT2 function in cells, causing an increase in the levels of 
tubulin acetylation.   
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Figure 25:  Pre-lethal 6OHDA Reduces NAD+ and NADH Levels 
SH-SY5Y cells were treated with either pre-lethal (A & B) or sub-lethal (C & D) 6OHDA.  NAD+ and NADH 
levels were determined via an enzyme cycling reaction and the levels were normalized to total protein.  (A & B) 
Significant reduction in both NAD+ and NADH levels was observed after pre-lethal injury.  (C & D) No reduction 
in levels of either NAD+ or NADH was observed after sub-lethal injury.  Mean +/- SEM, *p < 0.05 or nsp > 0.05 vs. 
Veh. Cont.  Compiled from 3 independent experiments.      
 
 The combined results suggest that different mechanisms are involved in the altered levels 
of tubulin acetylation that is observed.  After pre-lethal injury, significant reduction in levels of 
the co-factor NAD+ leads to diminished SIRT2 function in cells.  However, after sub-lethal 
injury, significant reduction in the intrinsic enzymatic activity of SIRT2 leads to diminished 
SIRT2 function in cells.  The end result of these changes is the same – an increase in the levels 
of tubulin acetylation. 
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4.9 RESCUE OF MT FUNCTION 
Significant changes are observed in the function of tubulin deacetylases, particularly SIRT2, 
after 6OHDA injury.  It is possible that altered function of tubulin deacetylases can, via 
deacetylase-dependent and/or -independent mechanisms, affect MT dynamics and neurite 
integrity in 6OHDA-treated cells.  Hence, the effects of rescuing impaired deacetylase function 
on MT dynamics and neurite integrity was examined.  
4.9.1 Rescue of MT Dynamics by Increasing NAD+ Levels 
Given the reduction in NAD+ levels in the pre-lethal injury model, the effects of rescuing 
cellular NAD+ levels on MT dynamics was examined.  The addition of NAD+ directly to the 
cellular medium has been shown to increase intracellular NAD+ levels in a variety of cell lines, 
including SH-SY5Y cells [203-205].  As consistent with the literature, the addition of NAD+ 
(1mM) for 6hr to the culture medium caused a significant increase in the levels of intracellular 
NAD+ (Fig. 26A).  To examine the effects of NAD+ restoration on 6OHDA-mediated increase 
in tubulin acetylation levels, cells were treated with vehicle or NAD+ for 6hrs before treating 
with a pre-lethal dose of 6OHDA (added directly to the medium containing NAD+).  6OHDA-
mediated increase in tubulin acetylation was significantly reduced in cells that were pre-treated 
with NAD+ (Fig. 26B & 26C).  To study the effects of NAD+ restoration on MT growth rate, 
cells expressing fluorescently-tagged EB3 were treated with NAD+ and pre-lethal 6OHDA as 
mentioned above.  MT growth rate was significantly reduced in response to 6OHDA treatment as 
before.  However, in cells that were pre-treated with NAD+, a rescue in MT growth rate was 
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observed (Fig. 26D).  These results suggest that restoration of NAD+ levels and hence SIRT2 
function rescues tubulin acetylation levels and MT dynamics in 6OHDA-treated cells. 
0
20
40
60
80
100
120
140
Veh. Cont. 150μM 4hr 6OHDA
M
T 
G
ro
w
th
 R
at
e 
(%
 C
on
t)
No NAD+ 6hr NAD+
*
0
0.0002
0.0004
0.0006
0.0008
0.001
0.0012
0.0014
Veh. Cont. 1mM 6hr NAD+
N
AD
+ 
(O
D
45
0 
/ u
g 
pr
ot
ei
n) *A B
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
Veh. Cont. 150μM 4hr 
6OHDA
Veh. Cont. 150μM 4hr 
6OHDA
Ac
-tu
b 
/ α
-tu
b
NAD+
ns
*
C D
Cont
150μM 4hr 
6OHDA
Ac-tub
α-tub
NAD+
150μM 4hr 
6OHDACont
 
Figure 26:  NAD+ Rescues Tubulin Acetylation Levels & MT Growth Rate 
(A)  Treatment of SH-SY5Y cells with 1mM NAD+ for 6hr leads to an increase in intracellular NAD+ levels.  (B & 
C)  Pre-treatment of cells with NAD+ (1mM; 6hr) protected against the 6OHDA-mediated increase in tubulin 
acetylation levels.  (D)  Pre-treatment with NAD+ reduced the impairment in MT growth rate caused by pre-lethal 
6OHDA.  Mean +/- SEM, *p < 0.05 or nsp > 0.05 as indicated.  Compiled from 3 independent experiments (for MT 
growth rate measurements, n = 75 – 100 EB3-mCherry comets per group). 
4.9.2 Rescue of MT Dynamics by Increasing HDAC6 and SIRT2 Levels 
The effect of directly increasing levels of the tubulin deacetylases on MT dynamics was also 
examined.  GFP, HDAC6-GFP, or SIRT2-GFP was transfected along with EB3-mCherry into 
SH-SY5Y cells and MT dynamics was examined via live cell imaging as before.  First, the effect 
of pre-lethal injury on MT growth rate was examined (Fig. 27A).  Overexpression of either 
HDAC6-GFP or SIRT2-GFP resulted in a reduction in the impairment of MT growth rate from 
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6OHDA-induced oxidative stress (Fig. 27A).  For sub-lethal injury, as shown earlier, the most 
significant alteration in MT dynamics was an increase in frequency of pauses / retractions.  This 
effect was again confirmed in cells expressing just GFP (Fig. 27B).  However, a significant 
rescue was observed in cells overexpressing HDAC6-GFP or SIRT2-GFP (Fig. 27B).  Therefore, 
the overexpression of either HDAC6-GFP or SIRT2-GFP protects against 6OHDA-induced 
alteration in MT dynamics. 
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Figure 27:  HDAC6 and SIRT2 Overexpression Rescues MT Dynamics 
(A)  SH-SY5Y cells expressing EB3-mCherry and either GFP, HDAC6-GFP, or SIRT2-GFP were treated with a 
pre-lethal dose of 6OHDA and MT growth rate was determined.  Rescue was observed in cells overexpressing 
HDAC6-GFP or SIRT2-GFP.  (B)  Frequency of pauses / retractions was determined in cells treated with sub-lethal 
6OHDA.  Increase in the frequency of these events was diminished by the overexpression of either HDAC6-GFP or 
SIRT2-GFP.  Mean +/- SEM, *p < 0.05 as indicated.  n = 75 – 100 EB3-mCherry comets per group compiled from 3 
independent experiments.    
4.9.3 Rescue of Neurite Length 
Given that modulation of tubulin deacetylases affects MT dynamics, it was of interest to examine 
if rescue of MT dynamics can also rescue neurite integrity.  Differentiated SH-SY5Y cells were 
transfected with GFP and either pcDNA, HDAC6-FLAG, or SIRT2-FLAG and then treated with 
sub-lethal 6OHDA.  Control cells expressing SIRT2-GFP showed slightly reduced neurite 
lengths compared to pcDNA control, as consistent with literature [144].  Nonetheless, the percent 
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reduction in neurite length in response to 6OHDA-induced oxidative stress was lower in cells 
expressing HDAC6-FLAG and SIRT2-FLAG compared to pcDNA control (Fig. 28).  Hence, the 
rescue of MT dynamics also appears to rescue neurite length.  
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Figure 28:  HDAC6 and SIRT2 Overexpression Rescues Neurite Length 
SH-SY5Y cells expressing GFP and either pcDNA, HDAC6-FLAG, or SIRT2-FLAG were treated with sub-lethal 
6OHDA.  HDAC6 and SIRT2 were detected by FLAG immunofluorescence.  Rescue in neurite length was observed 
with either HDAC6 or SIRT2 overexpression.  Mean +/- SEM, *p < 0.05 as indicated.  n = 150 – 200 cells per group 
compiled from 3 independent experiments.    
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5.0  DISCUSSION 
5.1 6OHDA INJURY MODELS 
Two different paradigms of a PD-relevant oxidative stress injury were utilized in this study – a 
pre-lethal and a sub-lethal 6OHDA treatment.  The pre-lethal model involved a relatively higher 
dose and shorter time (hours) course of 6OHDA exposure.  Such a model allows one to 
accelerate an injury that may occur over a long period of time.  However, to better understand 
neurodegenerative processes, a more long-term oxidative injury would be needed.  Hence, in 
addition to the pre-lethal 6OHDA model, a sub-lethal injury model involving a longer time 
course (days) was also developed.  Furthermore, for the sub-lethal model, SH-SY5Y cells were 
differentiated to a more mature neuronal phenotype where long neuritic processes are present.  
This allowed for the study of neurite biology, which is very relevant to PD where axonal 
degeneration is one of the earliest events.  Studying oxidative injury via a pre-lethal and a sub-
lethal model can be very useful as similarities between the two models can help strengthen the 
observed findings whereas differences between the two models can help in identifying different 
mechanisms and in determining the relevance of the models to the study of PD.         
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5.2 OXIDATIVE STRESS AND MT DYNAMICS 
5.2.1 Studying MT Dynamics in Live Cells 
In this study, growing MTs were highlighted in living cells with the use of fluorescently-tagged 
end binding proteins.  This technique has been extensively characterized and utilized for the 
study of MT dynamics in living cells [177,185,194].  However, it is of importance to briefly 
discuss why this particular technique was chosen over some of the other common techniques.  
One alternative is the transfection of fluorescently-tagged tubulin, which would then be 
incorporated into growing MTs [174,206].  However, there are a couple of key limitations to this 
particular technique that would have made the study of MT dynamics in this study difficult.  
First, there is a high background in transfected cells due to unpolymerized fluorescently-labeled 
tubulin which would make finding individual MTs difficult.  Second, given that this technique 
strongly labels the entire MT lattice, it makes finding MT ends in cells with a dense network of 
MTs, such as along the neurites, very difficult.  Therefore, the use of fluorescently-tagged 
tubulin would not have been ideal in the cell culture model used in this study.   
Another alternative method to study MT dynamics in live cells is the use of Fluorescent 
Speckled Microscopy (FSM), which has also been well characterized [207,208].  In FSM, 
fluorescently-labeled tubulin is microinjected into cells where it mixes with the endogenous 
tubulin pool and incorporates into MTs, forming a “speckled” pattern of fluorescence along the 
MT lattice.  The advantage of this technique over transfection of fluorescently-tagged tubulin is 
the lower background fluorescence and the ease of following movements of the “speckles” with 
time.  However, the need for microinjection is a key technical limitation of this particular 
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approach and hence would make its use in this study, where extensive live cell imaging was 
carried out, suboptimal.  
  The use of fluorescently-tagged +TIPs provides a low-background and specifically 
highlights the plus-ends of MTs – making it quite easy to follow growing MTs, even in MT 
dense areas such as the neurite.  However, there are a couple of limitations to this technique as 
well.  First, there is variation in expression level of the transfected protein where in some cells 
the complete network of MTs is highlighted instead of showing the typical comet-like pattern.  In 
these cells, it has been shown that the MT behavior is abnormal.  This issue can be easily 
avoided by simply selecting cells where a comet-like pattern is observed [185,206].  Hence, one 
must be careful in selecting cells for MT dynamics analysis with this technique.  The other 
limitation of this technique is in the analysis of other parameters of MT dynamics, such as MT 
retraction.  During MT pauses or retractions, the MT ends are not as bright or invisible given that 
these proteins only bind to MTs during the growth phase.  Hence, it makes specific 
determination of parameters such as MT retraction rate difficult.  However, there are published 
algorithms that can be used to determine such aspects of MT dynamics [177].  Nonetheless, for 
the study of certain parameters of MT dynamics, such as growth rate and frequency of pauses, 
the use of fluorescently-tagged +TIPs is preferred over the other alternatives.             
5.2.2 MT Dynamics in Oxidatively-Stressed Cells 
In response to 6OHDA-induced oxidative stress, a significant alteration in MT dynamics was 
observed.  Specifically, MT growth rates were reduced in 6OHDA treated cells.  This effect was 
more robust after pre-lethal injury as compared to sub-lethal injury.  Hence, other parameters of 
MT dynamics were also examined after sub-lethal injury, which showed increased frequency of 
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MT pauses/retractions.  The observation of significant alterations in MT dynamics in both the 
pre-lethal and sub-lethal models strengthens the conclusion that oxidative stress impairs MT 
function in neuronal cells.  Furthermore, utilization of the sub-lethal injury model makes the 
results more relevant to the neurodegenerative process seen in PD. 
How could oxidative stress affect MT dynamics?  One mechanism is through the direct 
oxidative modification of the tubulin heterodimer, specifically cysteine residues as there are 12 
in α-tubulin and 8 in β-tubulin [105,181].  Oxidation of cysteine residues of tubulin by a variety 
of agents has been shown to reduce tubulin polymerization rate [178-183].  Along the same lines, 
the addition of various disulfide reducing agents restores a considerable portion of the 
polymerization activity [178-180].  Certain cysteine residues that are “assembly-critical” have 
been proposed, however whether these are specifically oxidized and involved in the reduction of 
polymerization activity after oxidative stress is still uncertain [180,181].  Furthermore, 
methionine oxidation (26 methionine residues in the tubulin heterodimer) is another modification 
seen after treatment with certain oxidants (e.g. hypochlorous acid), although whether such a 
modification affects tubulin polymerization is still uncertain [180].  Nonetheless, given its 
abundance in neurons, tubulin is a likely target for oxidative modification.   
Another key mechanism by which MT dynamics is regulated is through MAPs.  As 
discussed extensively in the introduction, these proteins regulate many aspects of MT function, 
such as polymerization rate and stability.  Key members of the MAPs are the EBs as they 
regulate MT dynamics as well as the binding of other +TIPs to MTs.  Altered binding of EBs to 
MTs, which is thought to occur primarily via electrostatic and hydrophobic interactions, can 
therefore significantly alter MT dynamics [84,85].  Interestingly, H2O2 treatment has been shown 
to alter EB1 function [174].  6OHDA-induced oxidative stress was shown in this study to affect 
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EB1 levels and comet length without significantly affecting the overall MT organization.  
Reduced comet length is correlated with reduced MT growth rates and therefore is a nice 
confirmation of the live cell imaging results [175-177].  Given their important role, reduced EB1 
levels would be expected to reduce MT growth rate and increase frequency of MT pauses and 
retractions, which is exactly what is observed in response to 6OHDA treatment in this study.  
Hence, altered function of EB1 and perhaps other +TIPs could explain the altered MT dynamics 
that is observed.  It is currently unclear how oxidative stress could impact EB stability and 
interactions with MTs.  Oxidative modification could directly modify EB proteins or could 
activate signaling cascades that lead to post-translational modifications, such as phosphorylation.  
Although not much is known about EB phosphorylation, there have been numerous studies 
examining the phosphorylation of other +TIPs and its impact on MT binding [209-214].  
Phosphorylation of these +TIPs (e.g. by glycogen synthase kinase-3β [GSK3β], protein kinase A, 
and mammalian target of rapamycin [mTOR]) can reduce interactions with MTs as well as with 
other +TIPs.  Interestingly, 6OHDA can regulate the activity of various kinases, including 
GSK3β and mTOR [215-217].  Hence, phosphorylation of +TIPs may be one mechanism by 
which 6OHDA can affect MT function.               
5.3 OXIDATIVE STRESS AND TUBULIN ACETYLATION 
5.3.1 Tubulin Acetylation in Oxidatively-Stressed Cells 
Tubulin PTMs represent another way in which MT function is regulated and includes 
modifications such as acetylation, tyrosination and detyrosination, polyglutamylation, 
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palmitoylation, polyglycylation, and phosphorylation [97,98].  These modifications regulate the 
binding of MAPs to MTs and play an important role in neuronal differentiation, transport of 
cargo, axon guidance, and synapse formation.  With both pre-lethal and sub-lethal 6OHDA 
injury, a significant increase in levels of tubulin acetylation was observed.  A significant portion 
of this study was dedicated to determining the mechanism(s) by which levels of tubulin 
acetylation change after 6OHDA treatment.  Given that oxidative stressors, e.g. H2O2 and 
cigarette smoke, has been linked to altered localization, levels, and/or activity of various 
HDACs, the effects of 6OHDA-injury on the two known tubulin deacetylases, HDAC6 and 
SIRT2, was examined. 
It was found that 6OHDA did not significantly alter the subcellular localization of 
HDAC6 and SIRT2.  This was expected since the both are cytoplasmic proteins.  Although a few 
studies have shown that nuclear localization can occur in some cases in certain cells, no nuclear 
HDAC6 or SIRT2 was observed in control or treated SH-SY5Y cells [124,138,143].  The 
experiments in this study were carried out via immunofluorescence and hence very small 
changes in subcellular localization might be missed.  Therefore, one cannot rule out that some 
alteration in HDAC6 and SIRT2 distribution is occurring with 6OHDA treatment.  Although, 
given the nature of the acetylation changes that are observed, it would be safe to argue against 
small changes in subcellular localization as a possible mechanism. 
The effect of 6OHDA injury on the protein levels of HDAC6 and SIRT2 was also 
examined.  Levels of HDAC6 were not altered in response to either pre-lethal or sub-lethal 
6OHDA.  For SIRT2, although not statistically significant, pre-lethal dose of 6OHDA caused a 
trend towards a reduction in protein levels, which was a consistent observation in the majority of 
the replicates.  No such consistent pattern was observed for sub-lethal injury despite the 
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quantified results showing a trend towards an increase.  Hence, in the pre-lethal injury model, it 
is possible that reduced SIRT2 levels contribute to an increase in levels of tubulin acetylation.   
However, since these trends were not statistically significant, other possible mechanisms 
were explored.  Furthermore, tubulin acetylation level at earlier 6OHDA time points (e.g. 30min) 
is elevated but no reduction in SIRT2 protein levels is observed (data not shown).  Therefore, 
after pre-lethal as well as sub-lethal injury, there must be another mechanism(s) that can explain 
the increased levels of tubulin acetylation.  
The deacetylase activity of HDAC6 and SIRT2 was also examined in response to 
6OHDA-induced oxidative stress.  Utilizing an acetylated substrate, the deacetylase activity of 
immunoprecipitated endogenous HDAC6 and SIRT2 was studied.  For HDAC6, no significant 
change in activity was observed after a pre-lethal or a sub-lethal 6OHDA injury.  It is important 
to mention again that these assays were carried out with the use of a synthetic peptide that has 
been acetylated (as provided by the manufacturer).  These substrates are designed based on either 
a standard ε-acetyl-lysine or based on acetylated sites/regions found in various proteins, 
including p53 and histones.  Therefore, different substrates have preferences for different 
HDACs, which is confirmed by the manufacturer and recommendations are provided in selecting 
the ideal substrate.  Although a couple of other substrates were also used for HDAC6 deacetylase 
activity assays, no significant alteration was observed.  Nonetheless, it is still possible that 
HDAC6 in 6OHDA treated cells has an altered activity against tubulin in vivo.  Therefore, one 
cannot rule out that HDAC6 activity against tubulin is not affected by oxidative stress. 
SIRT2 deacetylase activity assays showed no change in activity in response to pre-lethal 
6OHDA injury, however a significant reduction was observed after sub-lethal 6OHDA injury.  
Hence, at least in the sub-lethal case, diminished SIRT2 activity can explain the increased levels 
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of tubulin acetylation.  With respect to the SIRT2 assays, it is important to discuss the antibody 
issues that were referred to earlier.  The SIRT2 antibody strongly detects SIRT2 at the correct 
molecular weight via Western blotting and has been confirmed for immunoprecipitation by the 
manufacturer.  However, in the immunoprecipitations done in this study, a strong band in 
addition to SIRT2 is also seen in the pulled-down sample.  This band is stronger than the SIRT2 
band that is pulled-down and hence is an issue to be addressed.  Based on the optimization assays 
carried out with the SIRT2 antibody, the deacetylase activity that is observed is NAD+ 
dependent.  Hence, it is safe to say that a NAD+-dependent deacetylase is being examined in the 
activity assays.  However, given that the unknown band (above IgG heavy chain; around 55 – 
60kDa) is much stronger than the SIRT2 that is pulled down, it is important to confirm that the 
activity observed is due to SIRT2 and not another sirtuin or an unknown deacetylase.  First, 
given the conditions in which the deacetylase reaction takes place (37oC with constant agitation), 
it is possible that much of the SIRT2 bound to the antibody is eluted and washed away in the 
subsequent wash steps.  Although this would not affect the deacetylase reaction itself, it would 
show much reduced protein levels when the levels are checked via Western blotting.  This could 
be one explanation for why such a small SIRT2 level is observed in the pulled-down samples.  
Furthermore, extensive analysis of the literature indicates that the molecular weights of the other 
six known sirtuins are not anywhere close to the size of the unknown band.  This provides some 
support that the observed NAD+-dependent activity likely results from SIRT2.  Nonetheless, 
deacetylase activity in SIRT2 knock-down samples will be examined, which should be able to 
confirm if the activity observed is in fact due to SIRT2. 
How could the deacetylase activity of SIRT2 be modified by oxidative stress?  Oxidative 
stress can cause reversible (e.g. disulfide bond formation and S-nitrosylation) and irreversible 
 71 
(e.g. carbonylation and tyrosine nitration) modifications to proteins that can affect their stability 
and function [218-220].  Evidence of oxidative modification to SIRT1 exists in the literature, 
which can provide some valuable insight to how SIRT2 function may be similarly affected since 
the catalytic domain is conserved in all SIRTs [120,221,222].  H2O2 has been shown to increase 
carbonylation on SIRT1 in cell culture (bronchial epithelial cell line BEAS-2B) and animal 
models (mouse lung) [221].  This modification was observed prior to a reduction in SIRT1 
deacetylase activity was seen and therefore could play a role in reducing SIRT1 activity [221].  
H2O2 also caused cysteine oxidation in SIRT1 [221].  Although not directly involved in the 
enzymatic reaction, some cysteine residues in the sirtuin fold domain are thought to be important 
for binding to the substrate, NAD+, and Zn2+ [223-225].  In fact, S-glutathiolation of certain 
cysteine residues in this region of SIRT1 has been shown to reduce its activation by resveratrol 
[222].  Hence, cysteine modification by oxidative stress could also reduce SIRT2 function.  
Another mechanism by which SIRT2 function could be regulated is via phosphorylation.  
Various cyclin-dependent kinases (Cdks) and the CDC14B phosphatase can regulate the 
phosphorylation status of SIRT2 and regulate its protein stability and enzymatic activity 
[144,226,227].  For example, p35–Cdk5 can phosphorylate SIRT2 at Ser-331, leading to 
inhibition of catalytic activity [144].  Interestingly, 6OHDA may up-regulate Cdk5 function in 
cell culture (e.g. PC12 cells) as well as animal models (e.g. striatal injection in rats) [228,229].  
Hence, there are a number of ways in which 6OHDA-induced oxidative stress can affect the 
enzymatic activity of SIRT2. 
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5.3.2 NAD+ Levels in Oxidatively-Stressed Cells 
Reduction in SIRT2 deacetylase activity was only seen in the sub-lethal 6ODHA injury model; 
hence increase in acetylated tubulin cannot yet be explained after pre-lethal injury.  Interestingly, 
NAD+ / NADH system is an important regulator of the redox state of the cell and their levels is 
found to be sensitive to oxidative stress [230].  Pre-lethal 6OHDA exposure caused a significant 
decline in intracellular NAD+ levels in this study.  However, no such reduction was observed 
after sub-lethal 6OHDA exposure.  Hence, reduction in the essential co-factor for SIRT2 can 
decrease its function in cells, leading to increased levels of tubulin acetylation.   
How could NAD+ and NADH levels change with oxidative stress?  One possibility is the 
overconsumption of NAD+.  NAD+ is consumed primarily by sirtuins, poly(ADP-ribose) 
polymerases (PARPs), ADP-ribosyl cyclases, and mono(ADP-ribosyl)transferases [202].  
PARPs are responsible for a significant portion of the NAD+ consumption in cells 
[202,204,231].  PARP-1 senses DNA damage and cleaves NAD+ into nicotinamide and ADP-
ribose, the latter is then polymerized onto nuclear acceptor proteins – ultimately leading to DNA 
repair [232].  In the case of oxidative stress, reactive oxygen species such as H2O2 and hydroxyl 
radical cause significant DNA strand breakage, which results in the over-activation of PARP-1.  
Abnormal activation of PARP-1 then depletes the cell of NAD+ and subsequently ATP, leading 
to significant cellular dysfunction and death [232].  This process is thought to play a key 
pathogenic role in a vast number of disorders, such as stroke, diabetes, myocardial ischemia, 
hemorrhagic and septic shock, various forms of inflammation, traumatic brain injury, and 
MPTP-induced parkinsonism [232,233].  Furthermore, oxidative stress can shift the balance of 
reduced pyridine nucleotides away from NADH and towards NADPH, which helps in the 
defense against ROS, by the regulation of various NADPH and NADH forming dehydrogenases 
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and NAD kinases [234-239].  Therefore, the above mentioned processes are likely mechanisms 
by which 6OHDA-induced oxidative injury causes depletion of cellular NAD+ and NADH.  
Another mechanism by which NAD+ and NADH levels could be reduced is if oxidative stress 
affects their synthesis.  There are two pathways for NAD+ synthesis, the de novo pathway that 
uses L-tryptophan as the precursor and the salvage pathway that uses nicotinamide and nicotinic 
acid as precursors [202].  There are numerous enzymes involved in the two pathways; however it 
is currently unclear if and how oxidative stress could affect their function.   
NAD+ and NADH levels are reduced after pre-lethal injury but not after sub-lethal 
injury.  A possible explanation for this difference is that after pre-lethal 6OHDA, there is a 
significantly higher degree of ROS exposure compared to sub-lethal 6OHDA– leading to greater 
consumption and reduced production by the mechanisms mentioned above.  Furthermore, it is 
possible that there is a brief dip in NAD+ / NADH levels after a sub-lethal dose is administered 
but by the time the measurements are made (24hr after the last dose), the levels return to 
baseline.  In this case, the temporary reductions in NAD+ levels could also contribute to elevated 
tubulin acetylation levels.     
5.3.3 Involvement of Tubulin Acetylases? 
Although the focus in this study was on the tubulin deacetylases, it is possible that the function 
of tubulin acetylases is modified after 6OHDA-induced oxidative stress.  As previously 
mentioned, tubulin acetylases have only been recently identified and hence not much is known 
about their regulation under oxidative conditions.  However, oxidative stress has been shown to 
increase histone acetyltransferase (HAT) activity [240-242].  A possible mechanism is through 
the activation of redox-sensitive signaling pathways, e.g. MAPK, that can regulate various 
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HATs, such as cAMP-response element binding protein (CBP), p300, and activating 
transcription factor-2 (ATF-2) [241].  It is possible that similar signaling pathways could activate 
tubulin acetylases as well and lead to increased levels of tubulin acetylation in 6OHDA treated 
cells. 
5.4 RESCUE OF MT FUNCTION 
5.4.1 Restoring Tubulin Deacetylase Function 
To better understand the consequence of tubulin acetylation on MT dynamics, rescue studies 
were carried out.  As discussed in detail in the introduction, evidence of acetylation regulating 
MT dynamics is a bit conflicting.  This is due primarily to differences in the assays used to study 
MT dynamics.  When more sensitive assays were used, such as time spent growing and pausing, 
modulation of tubulin acetylation resulted in altered MT dynamics.  Given the significant 
alterations in tubulin acetylation and deacetylase function observed in response to 6OHDA-
induced oxidative stress, rescue studies were performed where the effects of modulating 
deacetylase function on MT function was examined.  Restoring NAD+ levels in the pre-lethal 
6OHDA injury model where NAD+ depletion was observed resulted in rescue of tubulin 
acetylation levels as well as MT growth rate.  Hence, increasing NAD+ levels restores SIRT2 
function and subsequently reduces tubulin acetylation levels, which is thought to result in rescue 
of MT growth rate. 
Another mechanism by tubulin acetylation levels can be modified is through the 
manipulation of the tubulin deacetylases themselves.  Over-expression of HDAC6 and SIRT2 
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resulted in rescue of MT dynamics, e.g. growth rate and frequency of pauses/retractions.  Seeing 
rescue with both HDAC6 and SIRT2 suggests that increased tubulin acetylation is responsible 
for a significant portion of the alteration in MT dynamics.  Interestingly, in the pre-lethal injury 
model, overexpression of SIRT2 was able to rescue MT function similar to HDAC6 despite 
reduced NAD+ levels.  How could overexpression of SIRT2 in these cells with reduced NAD+ 
levels lead to rescue of deacetylase activity?  There are a number of enzymes that utilize NAD+ 
in their enzymatic reactions, with PARPs being the major consumers.  Hence, under normal 
conditions, SIRT2 competes with numerous other enzymes for the available pool of NAD+.  
With further reductions in NAD+ levels after oxidative stress, even less is available for SIRT2 
deacetylase activity.  It is hypothesized that the overexpression of SIRT2 makes it more 
competitive for the available pool of NAD+ – leading to an overall increase in tubulin 
deacetylase activity.  It is nonetheless interesting that the magnitude of rescue is similar to over-
expression of HDAC6.  It is possible that SIRT2 has a more robust deacetylase activity on 
tubulin than HDAC6 in this model.  Unfortunately, given the low transfection efficiency of these 
plasmids, it is difficult to confirm whether over-expression of HDAC6 and SIRT2 leads to a 
similar reduction in tubulin acetylation levels. 
5.4.2 Possible Mechanism(s) of Rescue 
How could tubulin acetylation affect MT function?  This question is of great interest in the MT 
field and the answer is yet to be determined.  It is important to note that majority of the studies 
examining the role of tubulin acetylation on MT function have been primarily through the 
manipulation of its deacetylases and recently acetylases.  Hence, it has been difficult to attribute 
the effects of manipulating these enzymes directly to the effects of acetylation of tubulin.  Given 
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that Lys-40, the most well studied acetylation site, is predicted to face the luminal surface of the 
MT polymer, it is difficult to comprehend how it could influence binding of MAPs.  However, 
these predictions were based on flat Zn sheets with random polarity, which is unlike MTs [105].  
It is possible therefore that this acetylation site could be facing the outside wall in properly 
assembled MTs.  Furthermore, it is also possible that acetylation at Lys-40 could cause 
conformational changes in the tubulin dimer that then is propagated to the surface of the MT 
polymer [243].  Acetylation of tubulin could also lead to severing of MTs by katanin, which 
would affect MT function [112].  Furthermore, the recently identified Lysine-252 acetylation site 
on β-tubulin by San (which modifies the tubulin heterodimers and not polymerized MTs) has 
been shown to reduce the incorporation of the acetylated tubulins into growing MTs [106].  In 
addition, some of the other recently identified acetylation sites are predicted to face the outside 
surface of the MT lattice and hence could regulate MT dynamics by affecting the binding of 
MAPs [107,243].  Further characterization of these sites and of the tubulin acetylases should 
provide key insight into the question of how tubulin acetylation can regulate MT function.  
It is also possible that the rescue observed by restoring deacetylase function could be 
independent of tubulin acetylation.  Interestingly, HDAC6 has been shown to interact with and 
regulate MAPs, such as tau and EB1 [133-136].  Tau is an important MT stabilizing MAP and 
EB1 is a key regulator of the dynamic properties of MTs [87,89].  SIRT2 has been shown to co-
localize and co-immunoprecipitate with HDAC6 and in vivo both proteins may be present in a 
complex that regulates MT function [143].  Hence, it is possible that restoring deacetylase 
function also restores binding of MAPs, such as EB1, to MTs and subsequently restores MT 
dynamics.   
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5.4.3 Restoring Neurite Integrity 
Given the significant alterations in MT function, MT-dependent processes would be expected to 
be affected.  One of the earliest changes observed in neurodegenerative diseases is axonal 
degeneration [4].  MTs play a key role in the development and maintenance of axons / neuritic 
processes.  Sub-lethal oxidative stress, which more closely mimics the injury that occurs in PD, 
causes reduction in neurite length.  It is unclear whether 6OHDA-induced oxidative stress 
impairs neurite growth or induces neurite shortening.  The neuritic process in differentiated cells 
attains the majority of its maximal length during the initial differentiation phase (before 6OHDA 
treatment).  There is limited neurite growth (< 10μm) in the vehicle treated cells after the start of 
the 6OHDA treatment.  Hence, 6OHDA-induced destabilization of MTs is likely causing neurite 
shortening but one cannot confidently rule out some contribution from impaired growth as well.  
Nonetheless, it is safe to say that neuritic integrity is compromised after 6OHDA-induced 
oxidative stress.  Neurite length was rescued in cells where MT function was restored by the 
overexpression of HDAC6 or SIRT2.  Given the importance of MT function in neurite growth 
and stability, it makes sense that restoring MT function also helps restore neuritic integrity.     
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6.0  CONCLUSION AND FUTURE PERSPECTIVES 
In response to 6OHDA-induced oxidative stress in neuronal cells, significant alterations in MT 
function were observed.  Specifically, oxidative stress reduced MT growth rate, increased 
frequency of MT pauses/retractions, altered EB1 levels, and increased levels of tubulin 
acetylation.  Along with these MT alterations, degeneration of neuritic processes, which is an 
early event in PD, was also observed in oxidatively-stressed cells.  Alterations in MT function 
were observed in both the pre-lethal as well as the sub-lethal oxidative stress models – helping to 
strengthen the conclusion of MT dysfunction after oxidative injury and also increasing the 
relevance to the degenerative process seen in PD.  Alteration in levels of tubulin acetylation was 
a result of impaired function of tubulin deacetylases, specifically SIRT2.  Furthermore, 
restoration of tubulin deacetylase function rescued MT function as well as the neuritic 
degeneration phenotype observed in response to 6OHDA, suggesting that oxidative stress 
impairs MT function, at least partially, by altering tubulin acetylation.  In addition to its impact 
on the integrity of the axon/dendrites and axonal trafficking of organelles, oxidative disruption of 
MT function could also affect gene expression.  In another set of experiments (see Appendix), 
oxidative stress disrupted MT-dependent nuclear transport, which could contribute to the 
selective declines in transcriptional responses of diseased dopaminergic neurons.  In all, this 
study provides support for the role of MT dysfunction in the degenerative processes seen in PD.  
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Figure 29 summarizes these findings and proposes a model of how 6OHDA-induced oxidative 
stress can lead to impairment in MT-dependent processes.   
6OHDA-
Induced 
Oxidative 
Stress
↑ Tubulin 
Acetylation
↓ EB1 Function
↓ MT Function
Impaired Tubulin 
Deacetylase
Function
↓ MT-Dependent 
Processes (e.g. 
Neurite Length & 
Nuclear Trafficking)
 
Figure 29:  Proposed Model of 6OHDA-Induced MT Dysfunction 
6OHDA-induced oxidative stress impairs tubulin deacetylase (specifically SIRT2) function, leading to increased 
levels of tubulin acetylation.  Increased tubulin acetylation subsequently impairs MT dynamics.  In addition, 
6OHDA-induced oxidative stress could also impair EB1 function, either directly or through impaired deacetylase 
function, and lead to decreased MT dynamics.  Decreased MT function subsequently affects MT-dependent 
processes, such as the integrity of the neurite and trafficking of transcription factors to the nucleus.  Restoring 
deacetylase function rescues MT function by reducing levels of tubulin acetylation and also possibly restoring EB1 
function – ultimately resulting in the restoration of key MT-dependent processes. 
 
The study of MT function in degenerating neurons of PD is an exciting avenue for future 
studies as genetic and toxin-based models of PD are beginning to identify significant alterations 
in MT function (see section 1.2.6 for details).  The current study utilizing an oxidative stressor 
adds to this growing evidence in the literature that MT dysfunction may play an important role in 
the neuronal degeneration that is seen in PD.  In addition to the parameters of MT function 
examined in this study and the many future experiments mentioned in the Discussion section, 
there are other aspects of MT function that are also of great interest to examine in future studies.   
Given the significant impact on tubulin acetylation in response to 6OHDA-induced 
oxidative stress, it would be very interesting to examine the effects of such stress on other 
tubulin PTMs.  Not only do these PTMs serve as markers of dynamic and stable pools of MTs, 
they can also regulate binding of MAPs and hence likely play a role in many aspects of neuronal 
function, such as differentiation, transport of cargo, axon guidance, and synapse formation.  
Evidence of MT regulation by tubulin tyrosination / detyrosination and polyglutamylation exists 
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in the literature [243].  Tyrosinated tubulin can recruit MT-depolymerizing kinesins and 
subsequently promote MT depolymerization [244].  Detyrosinated tubulin, which is often found 
along with acetylated tubulin on stable MTs, may also regulate MT dynamics by altering the 
binding of +TIPs, such as EB1 and Clip170 [97,245,246].  Polyglutamylation can recruit MT-
severing enzymes, e.g. katanin and spastin, and lead to MT depolymerization [247].  Hence, it is 
also possible that oxidative stress affects these tubulin PTMs and subsequently alters MT 
dynamics, which would be a very interesting direction for future studies.  
 One of the key functions of MTs is the trafficking of organelles and protein complexes 
along the axon.  As mentioned in the introduction, there is growing evidence of altered axonal 
transport in various genetic and toxin models of PD.  In addition, the study presented in the 
Appendix implicates a role for altered MT-dependent trafficking in the differential effects of 
6OHDA on the nuclear transport of transcription factors.  Motor proteins, such as dynein and 
kinesin, are a key component of MT-dependent trafficking and their recruitment to MTs is 
affected by tubulin PTMs [97,98,243].  Hence, with the 6OHDA-induced oxidative stress model, 
it would be very interesting to study the effects of altered MT PTMs on the binding of motor 
proteins.  Furthermore, it would also be of interest to examine the impact of such alterations on 
the trafficking of organelles, such as mitochondria and autophagosomes.  Given evidence of 
impaired axonal transport in PD, such studies would provide more evidence for the role of MT 
dysfunction in the neuronal degeneration that is seen in PD. 
The study HDAC6 and SIRT2 function is also of great interest in the field of PD 
[118,141,142].  Given their regulation of processes such as neuronal motility and differentiation, 
heat-shock protein chaperone system, transport of ubiquitinated proteins to aggresomes, and 
autophagic removal of protein aggregates and impaired mitochondria, these enzymes are likely 
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to play an important role in the neurodegenerative process seen in PD as well as in the 
development of therapeutic strategies.  Interestingly, SIRT2 inhibition has been shown to be 
protective against α-synuclein toxicity [248].  It is possible that increased tubulin acetylation 
leads to enhanced MT-dependent transport and clearance of the α-synuclein aggregates.  
However, the exact mechanism is still unknown and it is unclear if tubulin or another substrate is 
involved.  Furthermore, imbalance in the levels of acetylation is thought to be a common theme 
in neurodegenerative diseases [249].  Although this imbalance refers primarily to histones and 
the subsequent impact on gene expression, given the non-histone targets of many of these HATs 
and HDACs, the acetylation imbalance may also apply to non-genomic processes.  Balance in 
tubulin acetylation levels is important for proper MT function and hence imbalance towards 
either side would be expected to significantly affect MT function and have severe consequences 
for neuronal differentiation and survival.  Hence, the study of how oxidative stress modulates the 
function of the tubulin deacetylases could be an important aspect to understanding the 
pathogenesis of PD.    
To further implicate the role of MT dysfunction in neuronal degeneration seen in PD, it 
would be of great interest to study the effects of oxidative stress on MT dynamics and PTMs in 
dopaminergic neurons.  Furthermore, in addition to the 6OHDA injury model, it would be very 
informative to study effects of various genetic models of PD on MT function, including 
expanding on existing studies with α-synuclein, Parkin, and LRRK2 and adding other important 
contributors, such as PINK1 and DJ-1.  Doing so can help identify an underlying process that is 
involved in neuronal dysfunction and degeneration in PD, as is the case with mitochondrial 
biology and autophagy.  Advancement in understanding the mechanisms involved in neuronal 
degeneration are key to the development of therapeutic strategies for PD.  The question is what 
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should be the target of the therapeutic agent.  It would be ideal to prevent the degeneration from 
ever initiating, however by the time symptoms clinically manifest, the degeneration process is 
long underway.  In this case, it would be ideal to target the underlying degenerative event such 
that further degeneration can be prevented and some normal neuronal function can be restored.  
Antioxidant therapy could be promising if it can be successfully delivered early in the injury 
process and at a sufficient concentration to the midbrain dopaminergic neurons, which has thus 
far been difficult to do [71,250-254].  Additionally, if MTs play a key role in the degenerative 
process seen in PD, as the literature is beginning to suggest, then targeting MTs could provide a 
means by which neuronal function could be restored and further degeneration delayed or halted.  
Furthermore, an ideal therapeutic agent would be one that can affect the biology of multiple 
underlying events, such as the mitochondria and MTs.  Interestingly, olesoxime (cholest-4-en-3-
one, oxime; TRO19622), a molecule in the cholesterol-oxime compound family of mitochondrial 
pore modulators, has been recently shown to be protective in a wide-range of neurodegeneration 
models [255-258].  In addition to affecting the mitochondria, likely the mitochondrial 
permeability pore, it has also been shown to have significant MT dynamics promoting properties, 
such as enhancing EB1 accumulation at MT plus-ends and increasing MT growth rates [257].  
Neurite degeneration and mitochondrial trafficking impairments induced by the MT-
depolymerizing agent vincristine were prevented by olesoxime [257].  Given that this agent 
affects the biology of mitochondria and MTs, it is thought to be a promising therapeutic agent in 
numerous degenerative diseases.  In fact, it is in either clinical or preclinical stages for a variety 
of neurodegenerative diseases, such as amyotrophic lateral sclerosis, spinal muscular atrophy, 
peripheral neuropathy, multiple sclerosis, and PD [255].  This compound serves as an example of 
an agent that is promising due to its ability to regulate numerous processes that may be involved 
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in neurodegeneration and therefore, for the development of future therapeutic strategies, it 
further emphasizes the need to understand the key underlying events that lead to neuronal 
degeneration in PD.  
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APPENDIX 
ALTERED TRANSCRIPTION FACTOR TRAFFICKING IN OXIDATIVELY-
STRESSED NEURONAL CELLS 
The following work is a study of transcription factor trafficking in oxidatively-stressed neuronal 
cells.  This project represents the other significant portion of my efforts during graduate study.  
Utilizing the pre-lethal model of 6OHDA, the effects of oxidative stress on the nuclear 
trafficking of select transcription factors was examined.  The significance of the microtubule 
system for this process was also examined in this study.  In addition to the main body of work 
presented above, the following study also contributes to understanding the mechanisms by which 
oxidative injury could impact neuronal function in PD.   
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ABSTRACT 
 
Age-related neurodegenerative diseases are associated with alterations in gene expression in 
affected neurons.  One of the mechanisms that could account for this is altered subcellular 
localization of transcription factors, which has been observed in human post-mortem brains of 
each of the major neurodegenerative diseases, including Parkinson’s disease (PD).  The specific 
mechanisms are yet to be elucidated; however a potential mechanism involves alterations in 
nuclear transport.  In this study, we examined the nucleocytoplasmic trafficking of select 
transcription factors in response to PD-relevant oxidative injury, 6-hydroxydopamine (6OHDA).  
Utilizing a well-established model of ligand-regulated nucleocytoplasmic shuttling, the 
glucocorticoid receptor, we found that 6OHDA selectively impaired nuclear import through an 
oxidative mechanism without affecting nuclear export or nuclear retention.  Interestingly, 
impaired nuclear import was selective as Nrf2 (nuclear factor E2-related factor 2) nuclear 
localization remained intact in 6OHDA-treated cells.  Thus, oxidative stress specifically impacts 
the subcellular localization of some but not all transcription factors, which is consistent with 
observations in post-mortem PD brains.  Our data further implicate a role for altered microtubule 
dependent trafficking in the differential effects of 6OHDA on transcription factor import.  
Oxidative disruption of microtubule-dependent nuclear transport may contribute to selective 
declines in transcriptional responses of aging or diseased dopaminergic cells.   
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1.  INTRODUCTION 
 
Age-related neurodegenerative diseases, such as Parkinson’s disease (PD), Alzheimer’s disease 
(AD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD), are associated with 
alterations in expression of specific genes in affected neurons [1-3].  Transcription factors play a 
key role in the regulation of gene expression and the activity of many transcription factors is 
limited by their localization within the cytoplasm.  A number of mechanisms are utilized to 
direct sequestered transcription factors into the nucleus in response to specific signals [4-11].  
Since nucleocytoplasmic protein trafficking can be bidirectional [12], transcription factors 
exhibiting predominant nuclear localization may transit through the cytoplasm and also function 
in non-genomic signaling networks [13-16].  Interestingly, alterations in the subcellular 
localization of a number of transcription factors are documented in human post-mortem brains of 
each of the major neurodegenerative diseases [5].  Examples include cytoplasmic aggregation of 
phosphorylated (p)CREB (cAMP response element binding protein) and lack of nuclear pCREB 
in PD [17], reduced nuclear localization of Nrf2 (nuclear factor E2-related factor 2) in AD but 
not in PD [18], increased cytoplasmic ATF2 (activating transcription factor 2) levels in AD [19], 
and increased cytoplasmic:nuclear ratios of TDP-43 (TAR DNA-binding protein 43) in 
frontotemporal lobar dementias and ALS [20].   
Extensive evidence of oxidative damage to proteins, lipids, and DNA is found upon 
analysis of post-mortem brains of various neurodegenerative diseases, including PD [21-31].  
Furthermore, genetic and environmental models of various neurodegenerative diseases support 
the notion that oxidative stress plays a primary role in their pathogenesis [24-26].  In the case of 
PD, mutations or deficiency of proteins such as Parkin, PINK1 (PTEN-induced putative kinase 
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1), α-synuclein, DJ-1, and LRRK2 (leucine-rich repeat kinase 2), have been shown to increase 
susceptibility to oxidative stress-mediated cell death [32-34].  Parkinsonian mimetics such as, 6-
hydroxydopamine (6OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, 
and paraquat, generate reactive oxygen species (ROS) and cause neuronal death [35].  These 
studies suggest a key role for oxidative stress in the pathogenesis of these diseases. 
6OHDA has been widely used to study neuronal injury responses in PD.  It is an analog 
of catecholamine neurotransmitters that is taken up into cells by dopamine and norepinephrine 
reuptake transporters.  It is commonly used to model PD-relevant oxidative stress as it 
demonstrates an early autoxidation phase of ROS production and also has a delayed phase of 
mitochondrial ROS production [36].  Although used as an exogenous neurotoxin, there is 
evidence of spontaneous ring hydroxylation of dopamine in vivo, with elevated body fluid levels 
of 6OHDA detected in patients treated with L-Dopa [37,38]. 
6OHDA treatment leads to increased cytoplasmic accumulation of (p)ERK (extracellular 
signal-regulated kinase) [39] and decreased nuclear levels of GFP (green fluorescent protein)-
ERK2 [40] as well as decreasing the nuclear to cytoplasmic ratios of pCREB in SH-SY5Y cells 
and in primary midbrain neurons [17].  These findings are consistent with alterations observed in 
dopaminergic neurons in post-mortem PD brains [5].  CREB-regulated gene transcription, which 
is important for axon growth, mitochondrial biogenesis, and neuronal survival, was also 
repressed in 6OHDA treated cells.  Given the dynamic shuttling of transcription factors between 
the nuclear and cytoplasmic compartments, there are a number of mechanisms that could result 
in altered distribution of transcription factors in degenerating neurons, including 
compartmentalization, altered expression levels, sequestration in protein aggregates, and nuclear 
transport deficits [5].  Interestingly, 6OHDA impairment of CREB-mediated transcription (e.g. 
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Bcl2 [B-cell lymphoma 2] and BDNF [brain-derived neurotrophic factor]) was reversed with 
cAMP treatment, which activates CREB through mechanisms not requiring active nuclear import 
[17,41] – suggesting a possible impairment in the nucleocytoplasmic trafficking of CREB.  The 
observed steady state alterations in the distribution of transcription factors could result from 
altered nuclear import/export with significant consequences on neuronal survival.  The main goal 
of this study was to directly examine, in a neuronal cell line, the impact of 6OHDA-induced 
oxidative stress on distinct steps in the regulated nucleocytoplasmic trafficking of select 
transcription factors. 
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2.  MATERIALS AND METHODS 
 
2.1.  Cell Culture 
SH-SY5Y neuroblastoma cells (ATCC, Manassas, VA) were grown on 10cm cell culture dishes 
containing Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% heat-inactivated fetal calf 
serum, 2mM L-glutamine, and 10mM HEPES.  Cells were maintained at 37oC in a humidified 
5% CO2 incubator. 
 
2.2.  Plasmids and Transfections 
SH-SY5Y cells were transfected with LipofectamineTM 2000 reagent (Invitrogen, Carlsbad, CA) 
utilizing Opti-MEM® I reduced serum media (Invitrogen, Carlsbad, CA) according to the 
manufacture’s protocol at a final Lipofectamine concentration of 0.1%.  Cells were grown for at 
least 48hr before transfection and then allowed to express the protein of interest for another 24hr 
- 48hr before treatment.  GR-GFP and Nrf2-GFP plasmids were kindly provided by Dr. Ian 
Macara (University of Virginia) and Dr. Manabu Furukawa (University of Nebraska), 
respectively. 
 
2.3.  Drug Treatments 
6OHDA (Sigma, St. Louis, MO) was prepared in cold sterile water immediately before use.  
Dexamethasone (Sigma), a synthetic glucocorticoid hormone, was prepared at a stock 
concentration of 10-3M in 95% EtOH and used at a working concentration of 10-6M unless 
otherwise stated.  Cortisol (Sigma) was prepared at a stock concentration of 10-3M to 10-4M in 
100% EtOH and used at a working concentration of 10-6M to 10-7M unless otherwise stated.  For 
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antioxidant treatment, a metalloporphyrin antioxidant, MnTBAP (A.G. Scientific, San Diego, 
CA), was utilized at a final concentration of 150μM.  Colchicine (Sigma) and Paclitaxel (Sigma) 
were prepared in dH2O and DMSO, respectively, and used at the concentrations indicated in the 
text.   
 
2.4.  Monomeric Tubulin Extraction 
Cells treated with either vehicle or the drug of interest were washed in 37oC DPBS (Dulbecco’s 
Phosphate-Buffered Saline) and then incubated with tubulin extraction buffer (10mM PIPES, pH 
6.8, 50mM KCl, 2mM EGTA, 1mM MgCl2, 2M glycerol, 0.5% Triton X-100, 1mM Na3VO4, 
and protease inhibitor cocktail [Sigma]) for 15min at room temperature.  The resulting lysate was 
then centrifuged at 37oC at 16,000 x g for 2min to pellet any polymerized microtubules.  The 
resulting supernatant, containing soluble (monomeric) tubulin, was then subjected to Western 
blotting.  The protocol was modified from [42]. 
 
2.5.  Immunoblotting 
Cell extracts were collected and immunoblots were performed as previously described [43] with 
the following exception:  BioRad (Hercules, CA) gel running system with a 10% gel was used to 
separate proteins.  Primary antibodies used: anti-α-tubulin (1:5000; Sigma) and anti-GAPDH 
(1:10000; Abcam).  ImageJ was utilized for densitometry (from N ≥ 3 experiments).   
 
2.6.  Cell Toxicity Assay 
Cells were plated in 96-well plates and treated with 150μM 6OHDA for varying amounts of 
time.  LDH (lactate dehydrogenase) release assay was carried out according to the protocol 
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provided by the manufacturer (Promega, Madison, WI).  Spectramax M2 plate reader was 
utilized to read the fluorescent signal (Molecular Devices, Sunnyvale, CA).  Percent cytotoxicity 
was calculated by the following formula: 100 x [(Experimental – Medium Background) / 
(Maximum LDH release – Medium Background)].  Maximum LDH release was determined by 
treatment of cells with lysis buffer as per manufacturer’s protocol.   
 
2.7.  Quantitative image analysis and statistics 
An inverted epifluorescent microscope (Olympus IX71) was used for imaging and ImageJ (NIH) 
was utilized for quantification.  Nuclear:Cytoplasmic ratios were calculated from at least 50 
randomly imaged cells per replicate (and pooled from at least three replicates) by measuring the 
fluorescent intensity within a randomly distributed region of interest of fixed size within the 
nuclear and the cytoplasmic compartments.  Raw fluorescent intensity is shown in the figures.  
Nrf2 distribution was also scored into two categories: (1) cytoplasmic and (2) cytoplasmic and 
nuclear.  Example images of these categories are shown in the results section.  Each experiment 
was replicated at least three times.  Student’s t test was used to compare means between two 
groups.  One-way analysis of variance (ANOVA) followed by posthoc Tukey HSD test was used 
for multiple comparisons.  A p-value < 0.05 was considered statistically significant.  
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3.  RESULTS 
 
3.1.  Subcellular localization of GR in response to hormone 
The glucocorticoid receptor (GR) was used to examine the effects of 6OHDA-induced oxidative 
stress on bidirectional nucleocytoplasmic trafficking.  Transport of GR from the cytoplasm to the 
nucleus is hormone-dependent and bidirectional as hormone withdrawal triggers its export from 
the nucleus [12,44-46].  Therefore, both steps in the nucleocytoplasmic trafficking of this 
transcription factor are regulated and can be experimentally isolated.  SH-SY5Y human 
neuroblastoma cells were transfected with an expression vector for GR-GFP and treated for 1hr 
with either Dexamethasone (Dex), a synthetic glucocorticoid, or Cortisol (Cort), the primary 
circulating glucocorticoid in humans.  In the absence of Dex or Cort, GR-GFP is cytoplasmic in 
the majority of the cells (~60% on average) with the remainder of cells also showing some 
nuclear localization.  The mean fluorescent intensity within equal size nuclear and cytoplasmic 
regions (nuclear:cytoplasmic ratio) for untreated cells is on average around 1, as shown by the 
dotted line (Fig. 1).  A dose-dependent increase in nuclear transport of GR-GFP was observed 
with maximum nuclear localization attained at ≥ 10-7M Dex or Cort (Fig. 1). 
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Figure 1:  Dexamethasone / Cortisol Titration 
 
SH-SY5Y cells expressing GR-GFP were treated for 1hr with Dex or Cort at the indicated concentrations.  In the 
absence of either ligand, GR-GFP is cytoplasmic in the majority of the cells (~60%) with the remainder showing 
some nuclear localization as well.  The raw mean fluorescent intensity within equal size nuclear and cytoplasmic 
regions (N/C ratio) for untreated cells is approximately 1.  After hormone treatment, GR-GFP is primarily localized 
within the nucleus.  Nuclear:Cytoplasmic GR-GFP ratios were determined as noted in the Materials and Methods 
section.  Representative images from Dex treatment are shown.  Mean +/- SEM, *p < 0.05 vs. Veh. Cont.  Compiled 
from 3 independent experiments. 
 
3.2. 6OHDA treatment impairs nuclear import of GR 
With 150μM 6OHDA (dose where impaired CREB/pCREB localization is observed [17]), 
treatment for less than 6hr did not cause cell death (Fig. 2A).  To determine if 6OHDA treatment 
causes an impairment in nuclear import, GR-GFP expressing SH-SY5Y cells were first treated 
with 150μM 6OHDA for 1hr and 4hr and then treated with 1μM Dex for 1hr to induce the 
nuclear localization of GR-GFP.  As seen in Figure 2B and 2C, pre-treatment with 6OHDA 
impaired the hormone-dependent nuclear import of GR-GFP.  Significant reduction in the extent 
of nuclear import was also seen at doses varying from 90μM to 300μM and treatment times as 
early as 30min (data not shown).  
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Figure 2:  6OHDA Reduces GR Nuclear Import 
 
(A) LDH release assay showed no evidence of toxicity until 6hr of 6OHDA treatment (150μM).  Mean +/- SEM, *p 
< 0.05 vs. Veh. Cont. (B & C) GR-GFP expressing SH-SY5Y cells were exposed to 150μM 6OHDA for 1hr and 4hr 
and then treated with 1μM Dex for an additional 1hr.  Significant reduction in GR import was observed in 6OHDA-
treated cells.  Mean +/- SEM, *p < 0.05 vs. No Ligand; #p < 0.05 vs. Veh. Cont.  Compiled from 3 independent 
experiments. 
 
3.3.  Antioxidant treatment reverses 6OHDA-induced impairment in nuclear import 
6OHDA has the propensity to produce free radicals [36,47].  To determine whether the nuclear 
import impairment observed in 6OHDA-treated cells involves oxidative stress, SH-SY5Y cells 
expressing GR-GFP were treated with MnTBAP, a cell permeable SOD mimetic, 30min before 
or 30min after the start of 6OHDA treatment (150μM; 4hr) (Fig. 3).  When cells were treated 
with MnTBAP before being exposed to 6OHDA, a near complete rescue in GR-GFP nuclear 
import was observed (Fig. 3A).  When cells were first treated with 6OHDA for 30 minutes 
before the addition of MnTBAP, a partial protection was observed (Fig. 3B).  This is consistent 
with the observation that 6OHDA treatment as short as 30min is enough to cause some 
impairment in GR nuclear import (data not shown).  The rescue observed with MnTBAP 
 95 
treatment suggests an oxidative mechanism is responsible at least in part for the 6OHDA-
mediated reduction in GR nuclear import.        
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Figure 3:  MnTBAP Rescues 6OHDA-Induced Impairment in GR Nuclear Import 
 
SH-SY5Y cells expressing GR-GFP were treated with MnTBAP, a cell permeable SOD mimetic, 30min before (A) 
and 30min after (B) the start of 6OHDA treatment (150μM for 4hr).  A complete and a partial protection was 
observed with pre- and post-6OHDA treatments with MnTBAP, respectively.  Mean +/- SEM, *p < 0.05 or nsp > 
0.05 as indicated.  Compiled from 3 independent experiments. 
 
3.4.  Nuclear export of GR is not altered in 6OHDA-treated cells 
In addition to impaired nuclear import, enhanced nuclear export could also explain the altered 
transcription factor distribution observed in neurodegenerative diseases.  To study if nuclear 
export is affected by 6OHDA-induced oxidative stress, a hormone withdrawal study was 
performed in SH-SY5Y cells expressing GR-GFP.  Cort, the naturally occurring ligand for GR, 
dissociates rapidly from GR and is therefore better suited for studying the effects of hormone 
withdrawal [46,48].  SH-SY5Y cells expressing GR-GFP were first treated with 10-7M Cort for 
1hr to induce the nuclear localization of GR-GFP.  The cells were then withdrawn from the 
ligand for up to 4hr in the presence of either vehicle or 150μM 6OHDA.  No significant change 
in nuclear export of GR-GFP was observed in cells exposed to 6OHDA compared to vehicle 
control (Fig. 4). 
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Figure 4:  6OHDA Does Not Alter GR Nuclear Export 
 
SH-SY5Y cells expressing GR-GFP were treated with 10-7M Cort for 1hr and then withdrawn from the ligand in the 
presence of vehicle or 6OHDA for up to 4hr.  No significant impairment in nuclear export of GR-GFP was observed 
in 6OHDA treated cells.  Mean +/- SEM, nsp > 0.05 as indicated.  Compiled from 3 independent experiments. 
 
3.5.  6OHDA does not alter GR nuclear retention 
6OHDA-induced oxidative stress could damage the nuclear envelope or chromatin binding sites 
and therefore alter nuclear retention of GR.  To investigate this possibility, SH-SY5Y cells 
expressing GR-GFP were first treated with Dex for 1hr to fully induce the nuclear translocation 
of GR-GFP and then exposed to 150μM of 6OHDA from 2 to 6hr in the presence of Dex (Fig. 
5).  If 6OHDA-induced oxidative stress damaged the nuclear envelope or reduced GR binding to 
high affinity chromatin binding sites, an increase in ligand-bound cytoplasmic GR-GFP could 
occur.  However, no significant change in subcellular localization was observed – suggesting that 
6OHDA does not reduce GR-GFP nuclear retention or trigger its leakage from a “damaged” 
nucleus.  In combination with the results of GR nuclear import and export assays, our data 
suggest that 6OHDA-induced oxidative stress impairs the hormone-dependent nuclear import of 
GR.    
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Figure 5:  6OHDA Does Not Alter GR Nuclear Retention 
 
SH-SY5Y cells expressing GR-GFP were first treated with Dex for 1hr and then exposed to 150μM of 6OHDA 
from 2 to 6hr in the presence of Dex.  No significant change in nuclear retention of GR-GFP was observed.  Mean 
+/- SEM, nsp > 0.05 as indicated.  Compiled from 3 independent experiments. 
 
3.6.  Nrf2 translocates into the nucleus in response to 6OHDA 
One of the transcription factors that did not show reduced nuclear localization in post-mortem 
human PD brains is Nrf2, a key protein in the defense against cellular stresses.  Under basal 
metabolic conditions, Nrf2 is sequestered in the cytoplasm and targeted for proteasomal 
degradation via its association with Keap1 (kelch-like ECH-associated protein 1).  Upon 
exposure to ROS, electrophiles, or serum factors, Nrf2 dissociates from the Keap1 inhibitory 
complex and translocates into the nucleus, where it upregulates stress response genes [49-54].  
For this reason, studies of Nrf2 nuclear translocation typically involve pre-incubation under 
serum-deprived conditions to shift the basal distribution of Nrf2 towards the cytoplasm [54,55].  
SH-SY5Y cells expressing Nrf2-GFP exhibited reduced nuclear:cytoplasmic ratios when grown 
in low-serum media (1% FBS) for 24hr (Fig. 6A).  Serum deprivation also caused an increase in 
the percentage of cells with cytoplasmic localized Nrf2-GFP and a decrease in the percentage of 
cells showing both cytoplasmic and nuclear localization (Fig. 6B). 
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 Nrf2 nuclear localization in response to 6OHDA-induced oxidative stress was then 
studied (Fig. 6C).  Serum deprived SH-SY5Y cells expressing Nrf2-GFP were treated with 
increasing doses of 6OHDA (from 30μM to 150μM), which caused a progressive increase in the 
nuclear localization of Nrf2.  The results from cells treated with 150μM 6OHDA are shown in 
Figure 6C.  Quantitation of Nrf2-GFP localization revealed a decrease in the percentage of cells 
showing predominant cytoplasmic localization and an increase in the percentage of cells showing 
both cytoplasmic and nuclear Nrf2 localization.  These results are similar to the studies 
examining Nrf2 nuclear translocation in response to H2O2 treatment [54].  Thus, inhibitory 
effects of 6OHDA on nuclear transport are selective and influence the active nuclear import of 
GR but not of Nrf2. 
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Figure 6:  6OHDA Induces Nrf2 Nuclear Localization 
 
(A & B) Standard culture conditions elicit Nrf2 nuclear translocation.  To desaturate the assay, cells were incubated 
in low serum media (1% FBS) for 24hr and nuclear localization was quantified by two methods as described in the 
Materials and Methods section.  Example images of cells scored as cytoplasmic Nrf2-GFP or cytoplasmic + nuclear 
Nrf2-GFP are shown.  Mean +/- SEM, *p < 0.05 vs. 10% FBS.  (C & D)  Treatment of serum deprived SH-SY5Y 
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cells with 150μM 6OHDA caused an increased nuclear and a decreased cytoplasmic localization of Nrf2-GFP.  
Mean +/- SEM, *p < 0.05 vs. Veh. Cont.  Compiled from 3 independent experiments.         
 
3.7.  6OHDA increases levels of unpolymerized tubulin 
The nucleocytoplasmic trafficking of some transcription factors, including CREB [56] and GR 
[57,58], is dependent on microtubules (MTs) in some cells.  Hence, alterations in MT function 
due to 6OHDA-induced oxidative stress could help explain the selective trafficking impairments.  
This is of particular relevance given the alterations in MT function observed in several age-
related neurodegenerative diseases [59,60].  In the case of PD, both toxin (e.g. MPP+ and 
rotenone) and genetic (e.g. α-synuclein and LRRK2) models implicate impaired MT function as 
a common pathway of neuronal degeneration [61-64].   
We investigated the effects of 6OHDA-induced oxidative stress on polymerization of 
tubulin.  We first determined the effects of MT-altering agents, colchicine and paclitaxel, on the 
levels of unpolymerized tubulin (Fig. 7A).  SH-SY5Y cells were treated with either vehicle, 1μM 
colchicine (2hr), or 50nM paclitaxel (1hr) and then incubated with tubulin extraction buffer to 
extract monomeric tubulin.  Colchicine increased and paclitaxel reduced the levels of monomeric 
tubulin, respectively, while not significantly affecting the levels of total tubulin (Fig. 7A & 7B).  
These concentrations of MT-altering agents did not cause cell death (data not shown).  We then 
examined the effects of 6OHDA on the levels of unpolymerized tubulin.  SH-SY5Y cells were 
treated with 150μM 6OHDA from 1hr to 4hr after which monomeric tubulin was extracted.  
Cells treated with 6OHDA showed increased levels of monomeric tubulin (Fig. 7C).  Levels of 
total tubulin were not altered in 6OHDA-treated cells (Fig. 7D). 
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Figure 7:  6OHDA Increases Levels of Unpolymerized Tubulin 
 
(A) SH-SY5Y cells were treated with either vehicle, 1μM colchicine (2hr), or 50nM paclitaxel (1hr) and then 
incubated with tubulin extraction buffer to extract monomeric tubulin and resolved by Western blotting.  Colchicine 
increased and paclitaxel reduced the levels of monomeric tubulin, respectively.  (B) Whole cell extracts of 
colchicine and paclitaxel treated cells were subjected to Western blotting, which showed no significant changes in 
total tubulin levels.  (C) SH-SY5Y cells were treated with 150μM 6OHDA for 1hr and 4hr after which monomeric 
tubulin was extracted.  6OHDA-induced oxidative stress increased the levels of monomeric tubulin.  (D) Whole cell 
extracts of 6OHDA-treated cells were subjected to Western blotting, which showed no changes in total tubulin 
levels.  Mean +/- SEM, *p < 0.05 or nsp > 0.05 vs. Veh. Cont.  Compiled from 3 independent experiments.  
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3.8.  MTs regulate GR but not Nrf2 nuclear trafficking 
We then examined the effects of directly modulating MTs on the trafficking of GR and Nrf2.  
Colchicine and paclitaxel were utilized to disrupt or stabilize, respectively, the MT network in 
SH-SY5Y cells expressing GR-GFP and Nrf2-GFP (Fig. 8).  SH-SY5Y cells expressing GR-
GFP were exposed to these agents at doses and times indicated above and then treated with Cort 
to induce the nuclear translocation of GR-GFP.  MT stabilization using paclitaxel did not alter 
the nuclear import of GR-GFP, however a decrease in nuclear import was observed in cells 
where the MT network was disrupted by colchicine treatment (Fig. 8A).  Neither MT 
stabilization nor disruption significantly impaired Nrf2-GFP subcellular localization compared to 
vehicle in response to 6OHDA stress (Fig. 8B).  Thus, the effect of 6OHDA on MT stability was 
similar to that of colchicine, and colchicine recapitulated the selective nuclear import impairment 
elicited by 6OHDA. 
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Figure 8:  MTs Regulate GR but Not Nrf2 Nuclear Trafficking 
 
(A) GR-GFP expressing SH-SY5Y cells were treated with either paclitaxel or colchicine and then treated with Cort 
for 30min to induce GR-GFP nuclear import.  Reduced GR-GFP nuclear import was observed in colchicine treated 
cells but not in paclitaxel treated cells.  (B) Nrf2-GFP expressing SH-SY5Y cells were treated with either paclitaxel 
or colchicine and then treated with 150μM 6OHDA for 30min to induce Nrf2-GFP nuclear localization.  No 
significant impairment was observed with either MT-altering agent.  Mean +/- SEM, *p < 0.05 or nsp > 0.05 vs. Veh. 
Cont.  Compiled from 3 independent experiments. 
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4.  DISCUSSION 
  
In this study, we examined the effects of 6OHDA on the nucleocytoplasmic trafficking of two 
transcription factors that are sequestered in the cytoplasm, but utilize distinct mechanisms for 
release from cytoplasmic anchors and import into the nucleus.  Previously published work has 
demonstrated adverse functional effects of altered pCREB or pERK2 subcellular localization on 
midbrain dopaminergic neuron survival [17,39], but the mechanism underlying such localization 
changes remained unclear.  Utilizing a well-established model of regulated nuclear transport, the 
glucocorticoid receptor, we found that 6OHDA treatment elicited early impairments in nuclear 
import without causing reduced nuclear retention or enhanced nuclear export.  Treatment with an 
antioxidant rescued the defect in GR nuclear import, supporting an oxidative mechanism for the 
6OHDA-induced effects.   
While relatively high doses of H2O2 can affect nuclear transport through global 
mechanisms in non-neuronal cells [10], the effects of sublethal/prelethal oxidative stress has not 
been previously studied in neuronal cells.  Interestingly, the impaired nuclear import observed in 
our system did not result from global nuclear import failure as Nrf2 nuclear localization 
remained intact in 6OHDA-treated cells.  The selective nature of these effects suggests a specific 
alteration that impacts the subcellular localization of some but not all transcription factors.  Our 
in vitro results are consistent with observations that Nrf2 shows clear nuclear localization in 
post-mortem PD substantia nigra neurons [18], while kinases and transcription factors activated 
by trophic signals show abnormal cytoplasmic accumulation [5].  
Interestingly, GR has been linked to the regulation of the dopaminergic system, including 
through interactions with the nuclear receptor related 1 protein (Nurr1) – which is important for 
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dopaminergic differentiation and phenotype maintenance as well as being associated with PD 
[65-75].  Furthermore, glucocorticoids have been shown to play a protective role in models of 
PD, although the mechanisms may involve more than one cell type in the brain [66,69].  In any 
case, selective impairment of a subset of transcription factors in the aging or oxidatively stressed 
brain may account for downregulation of dopaminergic differentiation markers observed in PD 
models [76-82] and for alterations in neurotrophic gene expression observed in PD midbrain 
tissues [1,83-86].      
The mechanism(s) underlying the selectivity in nuclear trafficking of proteins observed in 
this model of parkinsonian injury and in diseased PD brains may be of particular relevance to 
chronic neurodegeneration.  Since not all transcription factors are affected, a global mechanism 
that would impair all nuclear transport, such as bioenergetic collapse, is unlikely.  This is further 
supported by the early time points at which the trafficking impairment becomes apparent.  The 
current data implicate a role for altered microtubule dependent trafficking.  Some transcription 
factors utilize MTs for their transport.  Indeed, a sequence within the parathyroid hormone 
related protein was recently found to efficiently transport fusion proteins into the nucleus via a 
MT facilitated “fast track” mechanism [87].  Oxidative stress (e.g. H2O2) has been linked to 
impaired MT function, such as decreased tubulin polymerization rate and MT growth rate [88-
91].  In our model, we found that 6OHDA increased the levels of free monomeric tubulin similar 
to colchicine, suggesting enhanced depolymerization and/or reduced polymerization.  
Furthermore, colchicine-mediated disruption but not stabilization of MTs mimicked the effects 
of 6OHDA in reducing nuclear import of GR without affecting Nrf2 import.  These results 
suggest that 6OHDA modulates transcription factor trafficking through effects on MT-dependent 
transport of transcription factors.   
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 In addition to altered MT dynamics, there are other potential mechanisms that could 
contribute to selective impairments in nuclear transport.  Oxidative injury, e.g. H2O2, has been 
shown to alter the distribution of the small G protein Ran, which is a key player in the classic 
import/export cycle [92-95].  Although such an alteration would be expected to affect nuclear 
transport of many proteins, it is possible that different transcription factors have differential 
sensitivity to the breakdown of the Ran gradient across the nucleus or utilize an alternative non-
Ran dependent mechanism for their nuclear import [11,96].  Another possibility is the 
involvement of carrier proteins for nuclear import, importins.  Different transcription factors 
utilize different importins for their nuclear import, as is the case for CREB, GR, and Nrf2 – 
hence oxidative stress-induced alterations in different importins could also help explain the 
observed selectivity [97-99].  Evidence of altered levels or localization of specific importins have 
been described in various neurodegenerative diseases [10].              
In summary, we have found that 6OHDA selectively impairs nuclear import through an 
oxidative mechanism that may involve alterations in MT-dependent trafficking of transcription 
factors.  Given the importance of transcription factors for regulating gene expression, alterations 
in their nucleocytoplasmic transport could have significant consequences for neuronal 
differentiation, function, and survival.  For chronic diseases such as PD, oxidative stress related 
to aging, the cellular handling of the oxidative catecholamine neurotransmitters, or mitochondrial 
pathology could contribute to reduced trophic and reparative transcriptional responses through 
selective impairments in nuclear import. 
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